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Redox alterations due to increased ROS production in heart cells have been 
implicated in several cardiovascular diseases, such as ischemia, hypertrophy, and 
myocardial infarction, but may also play a crucial role for the wanted and unwanted 
effects of pharmacological stimulation. Genetically encoded biosensors allow for the 
visualization of redox changes at real-time in a quantitative manner, but have not yet 
been applied to human heart models. In this study, the hypothesis was tested that 
the cytosolic glutathione (GSH) redox sensor Grx1-roGFP2 can be applied to record 
the GSH redox state in human cardiomyocytes and fibroblasts. The cytosolic 
glutathione redox sensor Grx1-roGFP2 was stably introduced into human embryonic 
stem cell-derived cardiomyocytes (HES2-CM) and human foreskin fibroblasts (HFF) 
via lentiviral transduction. The kinetics of the Grx1-roGFP2 sensor were determined 
in a cell type specific manner in HES2-CM and HFF under increasing concentrations 
of H2O2 (0.1 - 1,000 µmol/L), diamide (1 - 1,000 µmol/L), and DTT (0.1 - 1 mmol/L). 
This identified a more reduced EGSH in HES2-CMs (-289 ± 1 mV; n=56) compared to 
HFFs (-269 ± 2 mV; n=18). Subsequently, GSH redox state alterations were 
investigated upon ROS stimulation with angiotensin II and pharmacological 
stimulation with cardioactive reference compounds (levosimendan, omecamtiv 
mecarbil). To investigate cell specific GSH redox changes in a tissue context, 
engineered heart muscles (EHM) were generated by mixing either (i) Grx1-roGFP2-
HFFs and naive HES2-CMs or (ii) Grx1-roGFP2 HES2-CMs and naive HFFs in a 
collagen hydrogel. Force generating EHM were formed within 20 days and were 
subjected to an acute oxidative (H2O2) and reductive (DTT) challenge. GSH oxidation 
and reduction could be recorded optically and associated with a reduced and 
increased contractile performance in EHM. Taken together, GSH redox state can be 
recorded optogenetically in living human cardiomyocytes and fibroblasts in classical 
monolayer and EHM culture. Differences in EGSH suggest difference in redox related 
signalling in cardiomyocytes and fibroblasts which may have to be considered when 
interpreting redox responses to drugs or other stimuli at the whole heart level.  
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1.1 Cellular composition of the heart 
The human heart is a beating organ that consists mainly of cardiomyocytes, 
fibroblasts, endothelial cells, smooth muscle cells, and immune cells (Souders et al. 
2009). Cardiomyocytes (CM) comprise almost 30% of the total cell pool while the 
remainder 70% are non-myocytes (Tirziu et al. 2010) with the cardiac fibroblasts (CF) 
being the most abundant cell type (Souders et al. 2009, Tian and Morrisey 2012). To 
understand the functional mechanics of the heart, it is essential to understand the 
biology of interactions of these cells. 
 
Cardiomyocytes are contracting, striated and rod-shaped cells, which determine the 
performance of the heart. This energy dependent process depends critically on the 
provision of ATP produced in mitochondria. Actin and myosin filaments comprise the 
molecular machines that help the cell to contract. Furthermore, cardiomyocytes 
interact with their myocardial environment not only mechanically, but also by the 
secretion of cytokines and growth factors (Howard and Baudino 2014). 
 
Cardiac fibroblasts, similarly to cardiomyocytes, are of mesodermal origin and 
considered the main contributor to extracellular matrix (ECM) of the heart (Souders et 
al. 2009). In addition, they are capable of sensing and responding to biochemical 
stress by secreting cytokines and growth factors (MacKenna et al. 2000). The 
secretion of several factors such as Ang II, IGF-1, transforming growth factor-ß1 
(TGF-ß), endothelin-1 (ET-1) and FGF2 (Bouzegrhane and Thibault 2002, Bujak and 
Frangogiannis 2007, Manabe et al. 2002) can influence cardiomyocyte contractility, 
metabolism, and oxygenation (Tirziu et al. 2010, Tomasek et al. 2002). In the recent 
years, the role of cardiac fibroblasts for cardiac physiology and pathology has been 








1.2 ROS sources and redox signaling in the heart 
The beating heart requires ATP which for the most part (95%) is provided by 
oxidative phosphorylation in mitochondria and for a minor part by the glycolysis and 
the Krebs cycle; 70-90% is produced by oxidation of fatty acids, while 10-30% is 
produced by oxidation of glucose, lactate, ketone bodies, and amino acids (Doenst et 
al. 2013). A byproduct of oxidative phosphorylation is the generation of ROS. ROS 
are highly reactive free radical molecules containing oxygen (O2-, -OH, H2O2), which 
are implicated in a myriad of cellular pathways, defined as redox signaling (Burgoyne 
et al. 2012). In addition to the ROS production by the mitochondrial electron transport 
chain (ETC), there are several dedicated enzymes, such as the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases (NOX), NO synthases (NOS), xanthine 
oxidase (XO), and monoamine oxidases (MAO) that contribute to overall cellular 
ROS load (Burgoyne et al. 2012, Santos et al. 2016). A delicate interplay of ROS and 
antioxidants control the level of cellular oxidation and reduction and thus a number of 
biological processes (Figure 1). 
 
 
Figure 1: Sources of ROS and the consequences of high and low ROS 




Mitochondrial ROS is produced mainly by complexes I and III of the ETC (Doenst et 
al. 2013). MAOs generate H2O2 during catabolic reactions and XOs generate H2O2 or 
O2
- by using oxygen as an electron acceptor. NOS enzymes require 
tetrahydrobiopterin (BH4) as a co-factor for NO production. The lack of BH4 leads to 
enhanced O2
-  production which reacts with NO to ONOO-; peroxynitrite that leads to 
a further reduction in BH4 and can induce cell death by apoptosis and necrosis 
(Burgoyne et al. 2012, Chen et al. 2010). Finally, NOX enzymes are considered key 
players in cardiac ROS production. In human, this family of enzymes consists of 
seven isoforms (NOX 1-5 and dual oxidase 1-2), which require distinct subunits for 
their catalytic reactions (Lassegue et al. 2012, Santos et al. 2016). NOX 2 and NOX 4 
are respectively considered the main O2
- and H2O2 generating isoforms in the heart 
(Burgoyne et al. 2012, Hafstad et al. 2013, Lassegue et al. 2012, Sirker et al. 2011). 
NOX 2 is reported to be activated by angiotensin II (AngII), endothelin-1, growth 
factors, cytokines or mechanical forces. In contrast, NOX 4 is constitutively active; 
stimuli, such as hypoxia, endoplasmic reticulum (ER) stress, TGF-ß and ischemia 
have however shown to increase NOX 4 protein abundance (Burgoyne et al. 2012). 
 
Studies show that physiological amounts of ROS are necessary for cell survival, 
proliferation and function (Figure 1). Several signaling pathways are directly 
influenced by ROS (Figure 2) and its excess production and accumulation can 
damage a number of cellular/sub-cellular components such as membranes, proteins 
and DNA (Charles and Eaton 2008, Elahi et al. 2009, Handy and Loscalzo 2016, 
Sabri et al. 2003, Sarsour et al. 2009, Sawyer et al. 2002, von Harsdorf et al. 1999). 
Examples of ROS mediated regulation of cellular processes include the Na+-H+ 
exchanger (NHE) and mitogen-activated protein kinases (MAPK) (Sabri et al. 1998) 
as well as tyrosine kinase Src pathways, protein kinase C, GTP-binding RAS proteins 
(Amin et al. 2001, Nakamura et al. 1998, Takimoto and Kass 2007). Specifically in 
cardiomyocytes, high ROS contributes to cell dysfunction and cardiac remodeling 
(Cesselli et al. 2001) by stimulation of apoptosis signaling kinase-1 (Kwon et al. 
2003), activation of nuclear factor ĸB (NFĸB) (Takimoto and Kass 2007), and 
reduction of Ca2+ uptake by SR Ca2+ ATPase (SERCA) (Xu et al. 1997). In addition, 
ROS inhibits the L-type Ca2+ current (Fearon et al. 1999) and affects the release of 




sulphydryl groups of the ryanodine receptor (RyR) (Kawakami and Okabe 1998, Zima 
and Blatter 2006). Effects of ROS in cardiac fibroblasts are reported to involve: (1) 
activation of matrix metalloproteinases (MMP), which leads to fibrosis and cardiac 
remodeling (Siwik et al. 2001, Sorescu and Griendling 2002, Spinale 2002) and (2) 
induced CF proliferation (Cheng et al. 2003, Takimoto and Kass 2007). Accordingly, 
elevation of ROS is implicated in myocardial infarction, fibrosis, atherosclerosis, 
cardiac hypertrophy, ischemia-reperfusion, and heart failure (Bolli 1998, Giordano 




Figure 2: ROS pathways associated with cardiac hypertrophy and remodeling. 
Image taken from (Takimoto and Kass 2007). 
1.3 ROS regulation in redox state 
The term ‘redox state’ is linked with the redox equilibrium of redox couples inside the 
cell, such as reduced and oxidized glutathione (GSH/GSSG), thioredoxin (Trx/TrxSS) 
and other cysteine (Cys/CySS) containing proteins. The most abundant cellular 




an important role in cellular redox balancing and regulation (Hafstad et al. 2013, 
Kang et al. 2005). Nicotinamide adenine dinucleotide phosphate (NADPH) is the 
main source of reducing equivalents of the GSH and Trx proteins (Schafer and 
Buettner 2001). GSH/GSSG is considered the main cellular redox system and found 
in high amounts in most cell compartments (cytosol, mitochondria, ER and nucleus) 
(Mari et al. 2010, Schafer and Buettner 2001). In the cytosol, glutathione abundance 
has been reported to be within the range of 2-10 mmol/L (Hwang et al. 1992, Mari et 
al. 2010). In the ER enhanced oxidation is reflected by a higher abundance of GSSG. 
Mitochondria contain about 15% of the total glutathione pool (Mari et al. 2009, Ribas 
et al. 2014). The cellular and subcellular glutathione redox potential (EGSH) can be 
calculated using the Nernst equation, considering an equilibrium of EGSH and EroGFP2 
(Meyer and Dick 2010, Morgan et al. 2011). 
 
Basal levels and states of cellular ROS are altered by free radical scavengers such 
as superoxide dismutase (SOD), glutathione peroxidase and catalase. The balance 
of the constantly oscillating reduction and oxidation processes are described as the 
“redox state” of the cell (McCord 1988, Werns and Lucchesi 1989).  
 
In comparison to other ROS, H2O2 is the most stable ROS species and the 
mitochondria are the main compartments for H2O2 production. H2O2 is essential in 
intracellular redox signaling, signal transduction and plays a role in oxidative 
modifications of the sulfhydryl (thiol) group (-SH) of cysteines at the active site of 
enzymatically active proteins. Mammalian cells developed self-protective 
mechanisms to regulate and to protect themselves from the damaging H2O2 levels. 
This self-protecting mechanism could be an enzymatic or non-enzymatic system 
(Bienert et al. 2006, Malinouski et al. 2011, Veal et al. 2007). Antioxidant proteins 
such as glutathione, thioredoxin and peroxiredoxin play key roles in scavenging ROS 
(Giles 2006, Tew and Townsend 2011, Zhang and Martin 2014).  
 
When ROS is present in the cellular system, due to enzymatic activities or 
exogenous stimulation (Figure 3), SOD mediates the conversion of superoxide to 
H2O2. In the presence of H2O2, the stimulation of the glutathione system is facilitated 




oxidation of GSH to GSSG while detoxifying H2O2 into H2O (McCord et al. 1971, 
Weydert and Cullen 2010). The reverse reduction process is mediated by glutathione 
reductase (GR) that receives electrons from NADPH (Watson et al. 2003) and helps 
in the conversion of GSSG to GSH. Moreover, the GSH/GSSG ratio is itself affected 






Figure 3: ROS effects on glutathione and thioredoxin. Oxidation leads to disulfide 
formation (-SS-) while reduction resolves the disulfides to thiol (-SH) residues in 
classical redox couples. Reduced and oxidized glutathione (GSH and GSSG) and 
thioredoxin (Trx-SH and Trx-SS) protein and its dependence on ROS, SOD and 
Catalase are depicted. GSH/GSSG state is further influenced by the redox state of 





Thioredoxin, specifically Trx1, is known for the specific cardioprotective function in 
the heart (Yoshioka 2015). The thioredoxin is protonated by oxidoreductases such as 
thioredoxin reductase (TrxR) and oxidized in the presence of peroxiredoxin (Prx) 
which at the same time is reduced (Figure 3) (Powis et al. 2000, Powis and Montfort 
2001, Wood et al. 2003, Yoshioka 2015, Zhang and Martin 2014). Prx oxidation is 
typically analysed to determine the general state of oxidation in cells and tissue. The 
redox regulation of Prx is further detailed in Figure 4. Peroxiredoxins are important 
antioxidant enzymes and assist in maintaining low intracellular levels of H2O2. The 2-
Cys (Cys 51 and 172) peroxiredoxin enzymes are found in 4 different types (Prx 1,2,3 
and 4) (Riquier et al. 2014). These proteins contain Cys with some nucleophilic 
sulphur (S) on their side chains that are very reactive to oxidation (Griendling et al. 
2016, Nagahara et al. 2009).Formation of sulfenic (-SOH), sulfinic (-SO2H) and 
sulfonic (-SO3H) derivatives (Figure 4) due to oxidation lead to post-translational 













Figure 4: Peroxiredoxin redox regulation. Reduction of disulphides on peroxidatic 
(CYSP) and resolving cyteines (CYSR) of peroxiredoxin (Prx) dimers is mediated by 
thioredoxin (Trx). CYSP is oxidized to sulphenic (-SOH) residues and hyperoxidized 
to sulphinic (-SO2H) and sulphonic (-SO3H) residues, upon high H2O2 exposure.  
Image was adapted from (Hoyle and O'Neill 2015). 
1.4 Measurements of ROS and redox states 
Different strategies used to measure ROS and redox states in cells have been 
reviewed recently by Griendling et al (Griendling et al. 2016). Biochemical assays 
(e.g., dichlorodihydrofluorescein diacetate, amplex red, and dihydrorhodamine) have 
been routinely used to measure cellular redox changes. However, several limitations 
have been associated with such methods, including cell toxicity, oxidation artifacts, 
lack of dynamic measurements, and limited specificity (Forkink et al. 2010, Meyer 







1.4.1 Genetically modified fluorescent redox sensors 
In recent years, genetically modified methods were developed to help monitor 
intracellular redox state changes in cells. Hydrogen peroxide sensor (Hyper) is a real-
time, ratiometric sensor that is sensitive to H2O2. It is characterized by 2 excitation 
peaks at 410 and 500 nm and an emission at 519 nm; its signal changes are 
reversible (Belousov et al. 2006) with a fast reaction constant (Bilan et al. 2013). As 
for most fluorescent-protein sensors, pH effects on signal intensity need to be 
considered (Lukyanov and Belousov 2014). Improvements of sensors are generally 
by enhancing redox-coupling, dynamic range and localization of sensors to 
subcellular compartments (Albrecht et al. 2011, Ezerina et al. 2014). 
 
The first genetic redox sensing modifications were performed by adding cysteine 
residues at the N149C and S202C positions within the green fluorescent protein 
(GFP). Similar mutations were subsequently demonstrated to be effective in a redox-
active yellow fluorescence protein (rxYFP) (Ostergaard et al. 2001). When this 
modified sensor was subjected to redox processes, a spectral change occurred at 
404 nm and 512 nm due to a shift in H148 and Y203 positions resulting from the 
formation of the disulfide bond between C149-C202 that faces the chromophore 
(Maulucci et al. 2008). This process allowed the visualization of the signal in real time 
and the changes in spectral levels could be used to report absolute concentrations of 
reduced and oxidized glutathione (GSH and GSSG, respectively) residues in cells 
(Ostergaard et al. 2004). However, to overcome the slow reaction of protein 
equilibrium due to differing glutathione states, the protein was fused with a 
recombinant glutaredoxin enzyme (Bjornberg et al. 2006). This model was further 
improved with another redox sensitive probe roGFP2 (Meyer and Dick 2010). In their 
study, Meyer and Dick introduced cysteine residues in S147 and Q204 positions of 
wild-type GFP (wtGFP) and enhanced GFP (EGFP). These new cysteine residues 
are located on ß-strands 7 and 10, close to positions 148 and 204 facing the 
chromophore (Figure 5B). This allows the formation of intramolecular disulfide bridge 
between the two residues (Meyer and Dick 2010). The redox probe was named as 
roGFP1 (derived from wtGFP) when introducing C48S mutation, and roGFP2 
(derived from EGFP) when adding another mutation S65T (Dooley et al. 2004, 




of GSH/GSSG oxidation in a reduced environment due to their lower midpoint 
potential (-291 mV for roGFP1 and -280mV for roGFP2 (Dooley et al. 2004). 
Furthermore, they are ratiometric and have an increased signal to noise ratio or 
dynamic range, which is determined by the proportion of the maximum to minimum 
response of the excitation ratios (Hanson et al. 2004). Ratiometric analysis of roGFP 
probes are useful tools to visualize the oxidation and reduction equilibrium of 
glutathione/glutathione disulfide (GSH/GSSG) fluorescence ratio in real time at 400 
nm and 490 nm (Dooley et al. 2004, Hanson et al. 2004, Meyer and Dick 2010). In 
this study, we used the Grx1-roGFP2 redox sensitive probe to measure the cytosolic 
glutathione potential.  
1.4.2 Mechanism of redox sensing with Grx1-roGFP2 
There are several advantages of utilizing roGFP2 relative to roGFP1, including 
enhanced brightness and dynamic range. The anionic form of the roGFP2 
chromophore (490 nm) dominates over the protonated form (405 nm) at basal state, 
thus during oxidation due to the decrease in the anionic form and an increase in 
protonic form of the chromophore, a better signal could be obtained (Hanson et al. 
2004). In roGFP2, the mutation S65T adds further resistance to artifacts such as 
photoswitching (Meyer and Dick 2010). roGFP2 was fused to human glutaredoxin 
redox enzyme Grx1 to accelerate the thiol-disulfide exchange between roGFP 
molecules and glutathione (Gutscher et al. 2008). Grx1-roGFP2 was reportedly very 
sensitive to traces of GSSG in the reduced environment of the cytosol, as a result of 
the redox potential (EGSH) ranging between -240 mV and -320 mV (Lukyanov and 
Belousov 2014). The reversibility of the Grx1-roGFP2 biosensor signal includes three 
consecutive steps (Figure 5A). Oxidized glutathione (GSSG) reacts with the 
nucleophilic cysteine (C23) of Grx1, to form a Grx1-glutathione disulfide intermediate. 
The next step is to S-glutathionylate the roGFP2, by reacting with one of the thiols of 
roGFP2. S-glutathionylated roGFP2 per se is unstable; stability is achieved by 
internal disulfide-bridge (C147-C204) formation (Meyer and Dick 2010). Application of 
oxidants (H2O2) leads to conformational changes on the roGFP2 structure, due to 
disulfide bridge formation between ß-strand 7 and 10. Antioxidant challenge of the 




204 (Figure 5B). The fluorescent intensity changes of the signal at 405 and 488 nm 
upon oxidation and reduction are shown below (Figure 5C). 
 
 
Figure 5: Schematic view of Grx1-roGFP2 sensor in oxidized and reduced 
conditions. (A) Reversible three step mechanism of the biosensor. (B) The ß-sheet 
organization of reduced and oxidized roGFP2, with Cys 204 and Cys 147 on ß-
strands 7 and 10. (C) Fluorescence intensities at 405 and 488 nm of the oxidized and 
reduced probe. Image adapted from (Aller et al. 2013, Meyer and Dick 2010, Swain 
et al. 2016). 
1.5 Drug-ROS sensing and therapeutic opportunities 
In the sections above, ROS sources and the pathophysiological role of ROS 
production are introduced. Another aspect to be considered is the toxicity and 





Several classes of drugs have been investigated for cardiac toxicity and the 
underlying mechanism to produce ROS. For example, the anticancer drug 
doxorubicin (Dox) can induce mitochondrial dysfunction and lipid peroxidation due to 
damage of amino acids and DNA caused by ROS (Raschi et al. 2010, Sawyer et al. 
2010). Azidothymidine (AZT) induces ROS and NOS production (Kline et al. 2009, 
Kohler et al. 2009).  
 
Enhancers of cardiac contractility such as the calcium-sensitizer levosimendan 
(LEVO) and the myosin activator omecamtiv mecarbil (OME) are applied clinically in 
acute heart failure. Enhanced contractility typically results in enhanced ATP turn-
over, which may be compensated by enhanced mitochondrial ATP production as well 
as ROS generation. Interestingly, OME in contrast to LEVO, despite both being 
strong positive inotropes, seems to not increase ATP consumption. The specific 
mechanisms of action of LEVO include: (1) positive inotropic effect by enhanced 
calcium sensitivity of troponin C and (2) pre- and afterload reduction as a 
consequence of vasodilation due to the opening of ATP-sensitive potassium 
channels in smooth muscle cells (Parissis et al. 2007, Pollesello et al. 2016). In 
addition, a cardioprotective effect has been postulated for LEVO which appears to be 
linked mechanistically to the activation of the mitochondrial ATP-sensitive K+-channel 
(Farmakis et al. 2016, Parissis et al. 2008). In non-myocytes (human neutrophils) 
LEVO inhibits ROS production (Hasslacher et al. 2011). Furthermore, LEVO prevents 
the generation of ROS by myeloperoxidase enzyme (MPO), which is released by 
polymorphonuclear leukocytes (PMN) in heart failure (HF) patients (Hasslacher et al. 
2011). In human atrial biopsies, antioxidant effects of LEVO were reported to prevent 
cell death of cardiomyocytes and H2O2-induced contractile dysfunction (Parissis et al. 
2008, Sahin et al. 2007). Collectively, these data suggest an effect of LEVO on ROS, 
but do not specify whether ROS alterations occur in cardiomyocytes and fibroblasts. 
OME, also known as CK-1827452, enhances myosin-actin cross-bridge formation 
without an increase in total ATP or oxygen consumption (Nagy et al. 2014, Teerlink 
2009).  
 
In contrast to OME and LEVO, Angiotensin II stimulation directly affects ROS 
production (H2O2 and O2




signaling starts with the activation of G-protein-coupled receptor 1 (AT1R), which 
activates redox dependent targets (Rac, c-Src, protein kinase C; PKC) to stimulate 
O2
- production by NOX2 in the heart. When reacting with NO radicals, O2
- produces 
peroxynitrite, whereas dismutation with superoxide dismutase (SOD) results in H2O2 
production. AngII stimulation increases in cytoplasmic calcium (Ca2+), thus activating 
NOX5 to produce H2O2. Both H2O2 and ONOO
- then stimulate mitochondrial ROS 
that will activate NADPH oxidases in the cytoplasm (Figure 6) (Dikalov and 
Nazarewicz 2013). 
 
Previous studies have used a number of antioxidants to reduce ROS, but the lack of 
specificity and disturbance of the redox homeostasis contributed to the suboptimal 
efficacy of the so far reported approaches (Zhang et al. 2012). Another approach was 
to develop specific compounds that could target and inhibit ROS production enzymes 
and proteins modified by ROS (Dao et al. 2015). Dao et al. further highlight the 
strengths of each of these strategies with promising directions such as inducing Nrf2 
transcription by dimethyl fumarate (DMF) activators like BG12, an approach that has 
been reported to be effective in multiple sclerosis (Bomprezzi 2015, Kappos et al. 
2008). In general it can be concluded that targeting the mitochondrial pathway to 
modulate redox states in cells appears promising in diseases with ROS dysregulation 
(Brown et al. 2016). Also because of its translational potential it is important to 
develop experimental models allowing for a clear correlation of ROS activity and 
function; biosensors for a quantitative assessment of redox potentials appear 
instrumental also for the development of cardioactive drugs or to identify potentially 
limiting side effects (Santos et al. 2016). Accordingly, the strategy of this study is to 









Figure 6: Redox signaling pathway via AngII stimulation. Activation of GPCR and 
AT1R follows the activation of several molecules that stimulate NOX specific 
enzymes to produce ROS. Image adapted from (Dikalov and Nazarewicz 2013). 
1.6 Engineered heart muscle as a 3D model to study redox changes 
Engineered Heart Muscles (EHM) is a promising tool for in vitro studies in 
cardiovascular research (Tiburcy et al. 2017). In fact, several groups have proposed 
different engineered heart tissue models for applications in drug development (Hirt et 
al. 2014). The engineering of force-generating cardiac tissues were first reported in 
embryonic chick (Eschenhagen et al. 1997) and neonatal rat (Zimmermann et al. 
2000) models. Most recently, ring-shaped human EHM have been advanced to 
display several structural (for example anisotropic sarcomere assembly) and 
functional (for example positive force frequency relationship) properties of postnatal 




engineered myocardium, including angiotensin II and anthracyclines; angiotensin II 
enhanced EHM stiffness without reducing contractile performance; doxorubicin 
demonstrated the anticipated concentration dependent cardiomyocyte toxicity 
(unpublished data). Whether these effects are related to ROS production has not 
been studied so far. The use of redox reporters would facilitate these analyses. 
1.7 Aim of the thesis 
This study aims to (Figure 7): 
 
1) Establish stable Grx1-roGFP2 expression in human cardiomyocytes and 
fibroblasts to enable optogenetic recordings of GSH redox state in a cell type 
specific manner. 
 
2) Determine whether GSH redox state alterations under pharmacological 
stimulation can be monitored in human cardiomyocytes and fibroblasts. 
 









Figure 7: Overview of the strategy, methods, and aims used in this study. 
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2. Materials and Methods 
 
2.1 Cells 
An overview of the cell lines used in this study can be found in Appendix 2. The use 
of human embryonic stem cells was approved according to the German Stem Cell 
Act by the Robert-Koch-Institute (permit #12; reference number: 1710-79-1-4-16). 
2.1.1 TSA201 
Commercially available TSA201 cells were derived from human embryonic kidney 
and immortalized by transduction of the SV40 large T-antigen (Giovarelli et al. 1995). 
In this study, TSA cells were used to test the expression of GFP from pGIPZ-Grx1-
roGFP2 plasmid and as host cells of the packaging plasmids for the production of 
transgenic lentivirus.  
2.1.1.1 Cell Culture and maintenance of cell lines 
Passaging of TSA201 cells was performed at ~70% confluency. The cells were 
rinsed with 1x PBS and incubated for 3-5 mins in TryPLE (Invitrogen, 12604) to aid 
cell detachment. TryPLE was inactivated by the addition of 2x volume of TSA culture 
medium (Appendix 1) and the complete cell suspension was centrifuged at 300 x g 
for 5 mins. The cell pellet was triturated in TSA culture medium and counted using 
the CASY Model TT cell counter (Roche). The desired number of TSA201 cells was 
seeded in cell culture dishes or frozen for further usage. 
2.1.1.2 Freezing and thawing of TSA201 cells 
The cells were suspended (3 - 8 x 106 cells/ml) and triturated gently in freezing 
medium (see Appendix 1). The cells were transferred into cryovials (1ml/vial) and 
placed inside a freezing box at -80 °C to allow for controlled freezing. The cells were 
finally stored at -80 or -150 °C until further use. To thaw the cells, the cryovials were 
placed in 37 °C water bath for 2-3 mins, subsequently suspended in 9 ml of fresh and 
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warm TSA medium, and centrifuged at 300 x g for 5 mins to remove the DMSO. The 
cell pellet was further triturated in fresh TSA medium and then used for experiments. 
2.1.2 Human foreskin fibroblasts 
Human foreskin fibroblasts (HFF) were purchased from American Type Culture 
Collection (SCRC-1041; ATCC) and cultured in human fibroblast medium (Appendix 
1). Passages 25-30 were used for all the following experiments.  
2.1.2.1 Culturing and passaging of HFFs 
HFFs were passaged regularly when reaching a confluency of 80–90%. The cells 
were washed with pre-warmed (at 37 °C) PBS and then treated for 3-5 mins with pre-
warmed TryPLE (Invitrogen). To inactivate TryPLE, 2x volume of HFF medium was 
added to the detached cell suspension, which was triturated to produce a single cell 
suspension. To pellet the cells, the cell suspension was centrifuged at 300 x g for 5 
mins. The cells were then suspended in HFF medium, counted using the CASY 
Model TT cell counter (Roche), and seeded on non-coated culture flasks at the 
required density or frozen (see Section 2.1.1.2) for storage purposes.  
2.1.3 Human embryonic stem cells 
The human embryonic stem cell line (HES2) with a genetic modification of the 
ROSA26 locus to express a tandem dimer red fluorescence protein (tdRFP) was 
kindly provided by Prof. G. Keller (Toronto) (Irion et al. 2007). These cells were 
cultured on γ-irradiated HFFs feeder layers and then cultured in HESC medium (see 
Appendix 1). HES2 cells were passaged for expansion and single cell adaptation by 
using EDTA digestion solution (0.5 mol/L, pH 8, Applichem). After adaptation, these 
cells were differentiated into cardiomyocytes. 
2.1.3.1 Monolayer differentiation of HES2-CM 
Directed differentiation of HES2 was by a staged protocol (Tiburcy et al. 2017). 
Initially, HES cells were plated at a density of 5-10 x 105 cells/cm2 on feeder free 
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MatrigelTM (growth factor reduced; 1:60 diluted in 1x PBS; BD Biosciences)-coated 
flasks and cultured in HES cell-conditioned medium (Appendix 1) for 24 hours. HES 
cells were then rinsed with RPMI medium (Appendix 1) and kept in mesoderm-
induction medium (Appendix 1) for 3 days. HES cells were then rinsed with RPMI 
medium and cultured in mesoderm specification medium (Appendix 1) for 10 days. 
Highly purified cardiomyocytes were subsequently obtained with metabolic selection 
(Tohyama et al. 2013) in HES selection medium (0.28ml/cm2; Appendix 1).  
2.1.3.2 Single cell dissociation of HES2-CM 
The enriched cardiomyocytes obtained from the differentiation procedure (section 
2.1.3.1) were washed 2 times with 1x PBS and treated with Accutase digestion 
solution (Appendix 1) for 10 mins at RT, until the cells were detached from the flasks 
into single cells. The digestion solution was inactivated with 2-3 times the volume of 
serum-free CM medium and 5 µmol/L of Rock inhibitor (Appendix 1) was added into 
the cell solution. The harvested cells were centrifuged at 200 x g for 10 mins and 
further triturated in fresh serum-free medium. The cells were either re-plated onto 
MatrigelTM-coated flasks or used for further experiments. The purity of 
cardiomyocytes was determined by antibody labelling of sarcomeric α-actinin and 
assessed by Flow cytometry analysis software (Section 2.1.4; see Table 8 for 
antibody dilution and immunostaining protocol). 
2.1.3.3 Freezing and thawing of HES2-CM 
Cells were re-suspended (3 - 8 x 106 cells/ml) and triturated gently in freezing 
medium (Appendix 1). To thaw the frozen cardiomyocytes, the cryovial was warmed 
up 2-3 mins in a 37 °C water bath and gently triturated via a 2 ml pipette in 9 ml fresh 
CM medium. The cell suspension was centrifuged at 200 x g for 10 mins to remove 
DMSO. The cell pellet was re-suspended in fresh serum-free CM medium and plated 
onto MatrigelTM-coated flasks to recover for at least 5 days.  
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2.1.4 Flow cytometry 
Flow cytometry analysis was performed on both live and cells fixed in 70% ice-cold 
ethanol or fixed in 4% PFA for 15 mins at RT. 
2.1.4.1 Live cell analysis 
Live analysis was done to analyse the transduction efficiency in live cardiomyocytes 
and fibroblasts. In live cell analysis, the transduced and non-transduced cells were 
washed once with 1x PBS and then centrifuged at 300 x g for 5 mins. Cell pellets 
were washed with blocking buffer containing 5% FBS (Appendix) and centrifuged at 
300 x g for 5 mins. Meanwhile, Sytox solution was prepared (1:1,000 dilution) in 
blocking buffer with 5% FBS. The cells were then incubated in Sytox solution for 15 
mins at RT. After the incubation time, the cells were washed with 1x PBS and 
centrifuged at 300 x g for 5 mins. After 2 repeats of washing and pelleting, the cells 
were strained through a 70 μm cell strainer to remove cell clumps and subjected to 
flow cytometry analysis (LSR II Cytometer, BD Bioscience).  
2.1.4.2 Fixed cell suspensions analysis 
Cell suspensions previously fixed in ice-cold 70% ethanol or 4% Roti® Histofix, were 
strained though a 70 μm cell strainer and subjected to blocking buffer solution 
(Appendix 1) to permeabilize the cells for 10 mins at RT. The cells were incubated 
with specific primary antibodies for 45 mins at 4 °C (Table 8). At this step, to 
determine the purity of the differentiated cardiomyocyte population, CM-specific 
sarcomeric α-actinin antibody incubation was performed (Sigma-Aldrich, A7811, 
1:4,000; Table 8). Cell populations used as a negative control were incubated with a 
primary antibody against Immunoglobulin G (IgG) isotype control (R&D systems). 
After the incubation, the cells were washed (2x) with blocking buffer solution and then 
incubated with secondary antibody and the nuclei staining dye Hoechst (Invitrogen, 
H2570; 1:1,000) in the dark for 1 hr at 4 °C. For CM, goat anti-mouse Alexa 488 
(Invitrogen, A-110001; 1:1,000) was used as a secondary antibody. The cells were 
washed again (2x) in blocking buffer solution and re-suspended in PBS. The analysis 
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was performed using a LSR II Cytometer (BD Bioscience) and FACSDiva Software 
6.0 (BD Bioscience).  
2.2 Cloning of pGIPZ- Grx1-roGFP2 
The original plasmid pLPCX-Grx1-roGFP2 containing the biosensor coding sequence 
“Grx1-roGFP2” was a kind gift from Prof. Tobias Dick. The Grx1-roGFP2 coding 
sequence was excised and inserted into the pGIPZ lentiviral backbone (Open 
Biosystems). The cloning strategy is briefly described in Figure 8. 
 
(A) PCR amplification of “CMV-Grx1-roGFP2” by integrating XbaI and NotIrestriction 
enzyme cutting sites. To amplify the sequence of interest “Grx1-roGFP2”, forward 
and reverse primers with flanking restriction enzyme cutting sites on 5’ and 3’ 
ends were designed (Table 1). The amplified PCR product (5’-XbaI restriction site 
- CMV-Grx1-roGPF2 – NotI restriction site-3’) was integrated into the multiple 
cloning site (MCS) of a TOPO vector. 
 





Figure 8: Schematic overview of the cloning strategy. (A) The CMV-Grx1-
roGFP2 sequence of the original plasmid provided by Prof. Dick was PCR amplified 
and decorated with flanking XbaI and NotI restriction sites. The PCR product was 
inserted into a TOPO vector. (B) The CMV-turboGFP sequence in pGIPZ was 
replaced with CMV-Grx1-roGFP2 from TOPO vector. 
 
(B) Replacement of the CMV-turboGFPtag from the pGIPZ backbone by CMV-Grx1-
roGFP2 sequence with XbaI and NotI restriction cutting sites at 5’ and 3’ ends 
respectively. Restriction enzymes XbaI and NotI were used to remove CMV-
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turboGFP sequence from the pGIPZ backbone. The CMV-Grx1-roGFP2 
sequence was inserted via corresponding XbaI and NotI restriction sites yielding 
the plasmid pGIPZ-Grx1-roGFP2.   
 
Forward primers (sequence 5’-3’) 









F3 gctctagagcagatagtaatcaattacgg 29 
Reverse primer (sequence 5’-3’) 






Table 1: Forward and reverse primers used for PCR amplification of CMV-Grx1-
roGFP2. Primers F1 and R were chosen for PCR amplification. 
 
Each of the cloning steps includes technologies such as Polymerase Chain Reaction 
(PCR), RE digestion, agarose gel electrophoresis and extraction, ligation, 
transformation, plasmid DNA preparation, and DNA sequencing. The details of each 
of the techniques are explained in the following sections. 
2.2.1 Polymerase Chain Reaction (PCR) 
PCR amplifications of the biosensor coding sequence were done by using a T 
gradient PCR thermocycler (Biometra). The forward primers (F1-3) shown in Table 1 
were all used in combination with the reverse primer R. Parameters and the amounts 
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 A B C* D 
Primer combination F1 & R F2 & R F2 & R F3 & R 
dH2O (µl) 37.7 37.7 37.7 37.7 
Ex Taq10x Buffer (µl) 5 5 5 5 
dNTPmix (2.5 mmol; µl) 4 4 4 4 
Template (~200 ng; µl) 1 1 1 1 
Primer F (10 mmol; µl) 1 1 1 1 
Primer R (10 mmol; µl) 1 1 1 1 
ExTaq Enzyme (5 U/µl; µl) 0.3 0.3 0.3 0.3 
TOTAL (µl) 50 50 50 50 
 
Table 2: Components and parameters needed for PCR. *The difference to B is the 
annealing temperature (55 °C). 
 
The time and temperature protocol for each of the primer combinations is shown in 
Table 3 below. 
 
Program Temperature (°C) Time (sec) Cycles 
Initial denaturation  98 30 1 
Denaturation  98 10 
30 Annealing  
A B C D 
30 
66 66 55 61 
Elongation  72 30 
Final elongation  72 120 1 
End of program 4 ∞ 1 
 
Table 3: PCR protocol. Except of annealing temperature, all the other steps were 
identical for each primer combination. 
 
All PCR products were finally mixed with 6x DNA loading buffer (New England  
Biolabs, NEB) and separated by 1% agarose gel electrophoresis (Appendix 1). 
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2.2.2 Agarose gel electrophoresis 
To prepare a 1% agarose gel, 3 g of agarose was dissolved into 300 ml of 1x TAE 
running buffer (Appendix 1). The cooling of the gel solution was followed by the 
addition of 0.2 µg/ml of ethidium bromide (EtBr; Sigma Aldrich, #1239-45-8). The 
solution was poured into a gel tray and left to polymerise for 30 mins. Next, PCR 
amplified samples were loaded together with a 1 kb DNA ladder (Plus; Fermentas). 
Electrophoresis was at 100 V for 45 mins in 1x TAE running buffer (Appendix 1). 
Visualization of the DNA was under UV in the Gel Doc XR (BioRad) with subsequent 
analysis using the Quantity One Software (BioRad). 
2.2.3 Plasmid DNA extraction from agarose gels 
Extraction of DNA bands from agarose gels was performed as per manufacturer’s 
protocol (QIAquick gel extraction kit, QIAGEN). First, the desired DNA fragments 
were excised with a clean scalpel and put into 1.5 ml polypropylene (PP) tubes 
(Eppendorf). Each of the gel sections containing the DNA bands was weighed and 
300 µl of Buffer QG was added per 100 mg of gel. Subsequently, the samples were 
incubated at 50 °C for 10 mins with vortex intervals every 2-3 minutes. Complete 
dissolving of the gel was accompanied with the addition of 100 µl of isopropanol per 
100 mg of gel. The solution was placed into QIAquick 2 ml spin columns and 
centrifuged at 13,000 x g for 1 min. The flow-through was discarded and the 
QIAquick columns were washed with 0.75 ml Buffer PE. The washing step was 
followed by spinning at 13,000 x g for 1 min and the QIAquick columns were placed 
into clean1.5 ml PP tubes. 30 µl Buffer EB or pre-warmed (50 °C) H2O was added 
into the columns and left to stand for 1 min. The columns were centrifuged again at 
13,000 x g for 1 min and the concentration of the eluted DNA was measured by using 
a spectrophotometer (Nanodrop, ND-1000, Thermo Scientific). 
2.2.4 Ligation 
The DNA fragments eluted from the PCR of each primer combination (Table 4) were 
subjected to ligation reaction with either a TOPO vector (Figure 8A) or the pGIPZ 
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backbone (Figure 8B). For an optimal ligation reaction, the size and concentration of 
the vector and the insert was calculated with the formula below: 
 
𝐼𝑛𝑠𝑒𝑟𝑡 (𝑛𝑔) =  𝑉𝑒𝑐𝑡𝑜𝑟 (𝑛𝑔) 𝑥 
𝐼𝑛𝑠𝑒𝑟𝑡 (𝑏𝑝)
𝑉𝑒𝑐𝑡𝑜𝑟 (𝑏𝑝)
 𝑥 𝑟𝑎𝑡𝑖𝑜 
Subcloning into TOPO vector was performed according to the manufacture´s 
protocol. Ligation was performed by incubating the insert and the vector with T4 
ligase (NEB) at 16 °C overnight. The components of the ligation reactions for Figure 
8A and B are shown in Table 4. 
 
PCR A (CMV-Grx1-roGFP2) ligation to pGIPZ (Figure 8B) 
Vector (pGIPZ; 50 ng/µl; µl) 1.5 
Insert (PCR A; CMV-Grx1-roGFP2; µl) 0.5 
10 x T4 ligase Buffer (µl) 2 
T4 ligase (µl) 1 
dH2O (µl) 15 
Total (µl) 20 
 
Table 4: Ligation of insert and vector (step A-B as indicated in Figure 8). 
2.2.5 Transformation 
5 µl of the ligation mixture was added into 100 µl of TOP10 competent cells and 
incubated on ice for 30 mins. This step was followed by heat shock of the cells for 60 
sec at 42 °C with subsequent placement on ice for 2 mins. 450 µl of SOC medium 
(Invitrogen) was added into the mixture followed by incubation while shaking at 1 x g 
for 1 hr at 37 °C. 50-100 µl of the transformation reaction solution was plated onto 
PCR A (CMV-Grx1-roGFP2) ligation to TOPO vector (Figure 8A) 
Insert (PCR product; 100 ng/µl; µl) 1 
Salt solution (µl) 1 
TOPO vector (10 ng/µl; µl) 1 
dH2O (µl) 3 
Total (µl) 6 
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LB-agarose plates with 100 µg/ml ampicillin (Appendix 1) and allowed to air dry. The 
inverted plates were then incubated overnight at 37 °C. 
 
For TOPO vector subcloning mixtures, except for the plating on LB-agarose plates, 
all previously mentioned steps were the same. 30 minutes before plating the ligation 
mixture, 40 µl of X gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) and 40 µl 
of IPTG (Isopropyl β-D-1-thiogalactopyranoside) were plated onto the LB-agarose 
plates with ampicillin resistance. Using the blue-white colony screening strategy, 
detection of positive colonies (white coloured colonies) from negative colonies (blue 
colonies) can be performed. After plating the ligation mixture, the plates were 
incubated upside down at 37 °C in a dark environment.  
2.2.6 Miniplasmid DNA preparation 
The procedure for small scale plasmid DNA amplification was performed according to 
manufacturer’s protocol with NucleoSpin® Plasmid columns (Macherey-Nagel, 
#740499.250). First, 50 ml PP tubes (Falcon, BD) were filled with 4 ml LB-medium 
(Lysogeny broth; Appendix 1) and 100 µg/ml ampicillin. The colonies were picked 
from the agar plates and transferred into the LB-medium and incubated overnight (8-
12 hrs) at 37 °C and shaking at 220 rpm. The next day, the cultures were centrifuged 
at 11,500 x g for 30 sec. After spinning, the pellet of bacteria was re-suspended into 
250 µl of Buffer A1 (Macherey-Nagel) and mixed with 250 µl of lysis Buffer A2 
(Macherey-Nagel). The mixture was inverted 6-8 times and then incubated at RT for 
5 mins. After lysis, 300 µl of neutralisation Buffer A3 (Macherey-Nagel) was added 
into the lysed bacteria and the mixture was again inverted 6-8 times. In the next step, 
the mixture was centrifuged at 11,500 x g for 5-10 mins. The supernatant obtained 
from the last centrifugation was transferred into the Nucleospin collection tubes. The 
supernatants were centrifuged at the same speed as before for 1 min. The flow-
through was discarded from the collection tubes. The silica membranes of the 
Nucleospin columns were washed first with 500 µl of Buffer AW (Macherey-Nagel) 
and later with 600 µl of Buffer A4 (Macherey-Nagel). Both steps were followed by 
centrifugation at 11,500 x g for 1 min. The drying process of the silica membrane was 
done by another centrifugation for 2 mins. At the end, 30 µl of pre-warmed (at 50 °C) 
H2O was added to the center of the silica membrane and left to stand at RT for 1 min. 
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After spinning at 11,500 x g for 1 min, the eluted DNA was measured by a 
spectrophotometer (Nanodrop, ND-1000, Thermo Scientific) and subjected to RE 
digestion (2.2.7) or gel electrophoresis (section 2.2.2). 
2.2.7 Restriction enzyme digestion 
This technique was used to linearize the DNA plasmid to prepare for the ligation 
(CMV-Grx1-roGFP2 to pGIPZ, Figure 8B) and it can also be used for confirming the 
right clone/plasmid after a ligation step (subcloning of Grx1-roGFP2 into TOPO 
vector, Figure 8A). The reaction components and quantities required for the 
restriction enzyme digestion are shown in Table 5. 
 
                    Plasmids               
Reagents 
Reaction I (µl) 
TOPO- CMV-Grx1-roGFP2 
(2,000 ng) 




XbaI 1 1 
NotI 1 1 
Fast digest Buffer (green) 2 2 
H2O 12.9 13.8 
Total amount 20 20 
 
Table 5: Restriction enzyme digestion (figure 8B). 
 
DNA plasmids were linearized upon incubation with fast digest restriction enzymes at 
37 °C for 1 hr. Following the incubation, the linearized DNA plasmids were subjected 
to gel electrophoresis and the fragments were eluted as described in Section 2.2.3. 
The next step was integration of “CMV-Grx1-roGFP2” into pGIPZ backbone via 
ligation (Section 2.2.4). 
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2.2.8 Maxiplasmid DNA preparation 
After confirming the eluted plasmid DNAs, the next step was to purify high yields of 
the plasmid DNA. This step was performed according to the NucleoBond® Xtra kit 
(Macherey-Nagel). At first, a starter culture (4 ml) was prepared as described above 
(Section 2.2.6) with 100 µg/ml ampicillin. Incubation in a shaker (220 rpm) at 37 °C 
was for ~8 hrs. Once the bacteria reached exponential proliferation (log phase), 1 ml 
from the starter culture was added into 250 ml of LB-medium (containing 100 µg/ml 
ampicillin) in an Erlenmeyer flask and incubated in a shaker (220 rpm) for 12-16 hrs 
at 37 °C. The bacterial solution was centrifuged in an ultracentrifuge at 6,000 x g for 
15 mins at 4 °C. The supernatant was discarded and the pellet was resuspended in 
12 ml of Buffer RES + RNase A (Macherey-Nagel). This step was followed with the 
addition of 12 ml of Buffer LYS, which helped in lysing the bacteria. The lysate was 
gently inverted 5 times and it was incubated at RT for 5 mins. Next, the 
NucleoBond®Xtra Column and the filter were prepared and equilibrated by 25 ml of 
the Buffer EQU (Macherey-Nagel). After 5 mins of incubation, the bacterial lysate 
was neutralized with12 ml Buffer NEU (Macherey-Nagel) and gently inverted for a 
few times. The lysate was then poured through the equilibrated NucleoBond® Xtra 
Column filter and left to run until the liquid lysate was all filtered. Both the 
NucleoBond® Xtra Column and the filter were washed with 12 ml of Buffer EQU and 
then the filter was discarded. This was followed by washing of the NucleoBond® Xtra 
Column with 25 ml of Buffer WASH (Macherey-Nagel). DNA elution was done by 
adding 15 ml of Buffer ELU (Macherey-Nagel) and it was collected in a 50 ml falcon 
tube (BD). To precipitate the eluted DNA, 10.5 ml of RT isopropanol was added and 
the elution was first mixed thoroughly by vortexing, followed by centrifugation at 
8,000 x g for 30 mins at 4 °C. The supernatant was discarded and DNA pellet was 
washed with 70% ethanol at RT. The plasmid solution was centrifuged at 8,000 x g 
for 15 mins at RT. The resulting DNA pellets were left to dry (~30 mins) and then 
reconstituted in 100 µl Elution Buffer (Macherey-Nagel). The yield of the DNA was 
determined by a spectrophotometer (Nanodrop, ND-1000, Thermo Scientific). 
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2.2.9 DNA sequencing 
To ensure that the cloning process was successful and that the cloned constructs 
were correct, plasmid DNA was prepared for sequencing (Table 6) and then sent to 
sequencing by SeqLab (Göttingen). The primers used for sequencing were: forward 




      Plasmid DNA  





  dH2O (µl) Total (µl) 
2 1.4 3 10.6 15 
3 1.2 3 10.8 15 
5 1.2 3 10.8 15 
7 1.2 3 10.8 15 
8 1.5 3 10.5 15 
9 1.2 3 10.8 15 
15 1.1 3 10.9 15 
21 1.3 3 10.7 15 
 
Table 6: DNA sequencing reaction mixture. 
2.3 Transduction of Grx1-roGFP2 in HFFs and HES2-CM 
Stable transduction of Grx1-roGFP2 was achieved by lentiviral vector using standard 
protocols. 
2.3.1 Lentivirus production 
TSA201 were seeded in 10 cm cell culture dishes (Nunc) in low serum medium (0.5% 
FCS, 1% P/S; see Appendix). Once 70% confluency was reached, TSA201 cells 
were carefully washed once with PBS. Subsequently, 7 ml of the low serum medium 
was added. Transfection of pGIPZ-Grx1-roGFP2 together with psPAX2 (Addgene 
plasmid #12260) and pMD2.G (Addgene plasmid #12259) for lentiviral packaging 
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and VSV-G envelope expression (psPAX2 and pMD2.G were a kind gift by Prof. D. 
Trono), was done by using Polyfect reagent (Qiagen) according to manufacturer’s 
protocol (Table 7). 
 
Components for transfection Quantity 
pMD2.G 2 µg 
psPAX.2 3 µg 
GOI (pGIPZ-Grx1-roGFP2) 3 µg 
DMEM (w/o serum, w/o pen/strep) up to 300 µl 
Polyfect 80 µl 
Low serum medium (0.5% FCS, 1% P/S) up to 1 ml 
 
Table 7: Transfection reaction mixture for lentivirus production. 
 
The mixture was mixed by vortexing and then incubated for 10 mins at RT. 
Thereafter, low serum medium up to 1 ml was added and the complete mixture was 
layered onto TSA201 cells in a dropwise manner. After 72 hrs, the virus suspension 
was collected from the culture dishes into a 50 ml PP (polypropylene) tube (BD, 
Bioscience) and filtered through 0.45 µm filter (Millex® Syringe filter units, 30 mm; 
Merck Millipore) to remove cell debris. The virus suspension could be directly used to 
transduce HFFs and HES2-CMs. Alternatively virus was purified, concentrated, and 
frozen at -80 °C until further use. 
2.3.2 Lentivirus purification 
Purification of lentivirus was done by using a commercial Vivapure®Lentiselect40 kit 
(Sartorius; #VS-LVPQ040). The virus suspension obtained after 72 hrs of transfection 
(section 2.3.1) was passed slowly through a membrane absorber and collected as 
demonstrated in Figure 9. 






Figure 9: The assembled unit for lentivirus purification. The syringe is slowly 
filled with virus from the virus suspension and then passes carefully through the 
membrane absorber. Image adapted from (Vivapure® Lentiselect, Sartorius). 
 
After the virus suspension was filtered, the membrane absorber was washed and 
then eluted with 4 ml elution buffer according to the manufacturer’s instructions. The 
eluted viral solution was spun at 3,000 x g for 12 mins. The pellet was washed 1x 
with PBS and again spun at 3,000 x g for 12 mins. The titer of the lentiviral particles 
was determined to be >5 x 106 IFU/ml by using LentiXTM Go StixTM (Clontech).  The 
concentrated virus was aliquoted and stored at -80 °C. 
2.3.3 Lentivirus transduction of HFFs and HES2-CMs 
HFFs and HES2-CM at 70% confluence were transduced with lentivirus particles. On 
the day of the transduction, fresh medium (for HFF human fibroblast medium; for 
HES2-CM-serum free CM medium; see Appendix 1) together with polybrene (0.8 
mg/mL; see Appendix 1) was added onto the cells. On HFFs, fibroblast growth factor 
(FGF; 10ng/ml; Appendix1) was also added to the medium. Frozen aliquots of Grx1-
roGFP2 – lentivirus (100 µl/each) were thawed on ice and added to the medium 
inside the flasks. The cells were incubated with the virus for 72 hrs at 5% CO2 and 37 
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human fibroblast medium containing 1 µg/ml of puromycin (Invitrogen, #A11138-03) 
to select for successfully transduced cells. We initiated the selection of HES2-CM 
cultures with 0.1 µg/ml of puromycin, however after 48 hrs the cells were observed to 
be of poor quality and puromycin was subsequently withdrawn. 
2.4 Redox measurements of transgenic HFFs and HES2-CMs 
The transduced HFFs and HES2-CMs (section 2.4.4) were seeded in 24-well imaging 
plates (Zell Kontakt, #3231-20). For HES2-CMs, the imaging plate was first coated 
with Matrigel™ (1:120 in PBS) and incubated at 37 °C for 30 mins. The transgenic 
CMs were seeded as above (section 2.1.3.2). For HFFs, the seeding process in the 
imaging plate was performed as before (section 2.1.2.1). 
 
The redox measurements on the transgenic cells were done by using an inverted 
fluorescence microscope IX83 (Olympus). The establishment of the setup was done 
using a polychrome light source (Till Photonics) under the control of Visiview 
Software as previously described (Swain et al. 2016). The microscope was equipped 
with a cellVivo (Pecon) chamber to control the temperature (37 °C). Prior to 
measurements, transgenic HFFs and HES2-CMs expressing the Grx1-roGFP2 
sensor were washed and loaded with 300 µl of imaging buffer (with 1 mmol/L Ca2+ for 
HES-CMs and 2 mmol/L Ca2+ for HFFs; see Appendix 1). The cells were excited at 
405 nm and 488 nm and emission was detected via a CCD camera at 510 nm 
(Figure 10).  
 
 






Figure 10: Schematics of the fluorescence capture system used to measure 
redox changes in monolayer (transgenic HES2-CM and HFFs) and tissue 
(EHMs). Image adapted from (Swain et al. 2016). 
 
The pseudocolors for 405 and 488 nm signals were labelled blue and green, 
respectively. This could help to visualize the redox states of the cells during exposure 
to oxidants or antioxidant easily. Signal-to-noise ratio was calculated at 60 sec and 
180 sec exposure and images were acquired every 5 sec for HFFs and 10 sec for 
HES2-CMs. Once a stable baseline 405/488 nm ratio was reached (at 60 sec for 
HFFs and at 180 sec for HES2-CMs), the cells were challenged with oxidants such 
as hydrogen peroxide (H2O2: 0.1-1,000 µmol/L; Sigma-Aldrich, #7722-84-1) or 
Diamide (DA: 1-1,000 µmol/L; Sigma-Aldrich,#10465-78-8) and antioxidants such as 
dithiothreitol (DTT: 0.1-1 mmol/L; Sigma-Aldrich, #3483-12-3). The maximum 
oxidation and maximum reduction responses were used to calculate the reduction 
potential EGSH and dynamic range of the roGFP2 sensor in both HFFs and HES2-CM. 
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2.4.1 Calculation of EroGFP2 redox potentials 
The calculation of redox potential EroGFP2 was performed by applying the Nernst 
Equation and assuming that EroGFP2 and EGSH are in equilibrium (Meyer and Dick 
2010, Morgan et al. 2011): 
 




 ln  (
[𝐺𝑆𝐻]𝑥[𝐺𝑆𝐻] 
[𝐺𝑆𝑆𝐺]
) = 𝐸𝑟𝑜𝐺𝐹𝑃2 
 
R is the gas constant (8.315 J/Kmol), T is absolute temperature (298.15 K) and F is 
the Faraday’s constant (96.485 C/mol).  
 
Before calculating the redox potential EGSH, the degree of oxidation of the biosensor 
(OxDroGFP2) had to be defined (2). OxDroGFP2 was calculated based on the 
fluorescence intensities recorded at 405 and 488 nm excitation under reduced (DTT -
0.1-1 mmol/L) and oxidized (H2O2 - 0.1-1,000 µmol/L; DA - 1-1,000 µmol/L) 
conditions: 
 
 (2) 𝑂𝑥𝐷𝑟𝑜𝐺𝐹𝑃2 =
[roGFP2]ox
([roGFP2]red + [roGFP2]ox  )
 
 
The equation (2) can be transformed as below (3): 
 
(3) 𝑂𝑥𝐷𝑟𝑜𝐺𝐹𝑃2 =
I405 x I488red−I405red x I488
I405 x I488red−I405 x I488ox + I405ox x I488−I405red x I488
 
 
I is the fluorescence intensity at 510 nm under the indicated excitation wavelengths 
at maximally oxidized (ox) or reduced (red) conditions.  
 
Based on OxDroGP2 and the already defined sensor midpoint redox potential E°’roGFP2 
(-280 mV; (Dooley et al. 2004)) the redox potential EroGFP2 can be calculated (4): 
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The dynamic range of the biosensor was determined by considering the maximal 
H2O2 and DTT responses. Microscope settings (excitation light intensities and 
exposure times) were all standardized before the measurements. 
2.5 Redox response to reference compounds 
Both transgenic HFFs and HES2-CM were treated with angiotensin II (0.1-1,000 
nmol/L; Sigma-Aldrich, #4474-91-3), levosimendan (LEVO - 0.1-10 µmol/L; Sigma-
Aldrich, #141505-33-1) and omecamtiv mecarbil (OME/CK-1827452 - 0.1-10 µmol/L; 
AdooQ Bioscience, #A11206) to study potential effects on glutathione redox 
potential. After a stable baseline recording for 300 sec, 300 µl of each of the 
compounds at the specific concentrations were added onto HFFs and HES2-CMs 
(see Appendix 1). Fluorescence signals were recorded over 900 sec. The change in 
oxidation or reduction response were analysed using Visiview Software. 
2.6 Oxidized peroxiredoxin in fibroblasts and cardiomyocyte 
Oxidation at the protein level was studied after challenging HFF and HES2-CM with 
H2O2 (1 – 1,000 µmol/L) for 1 hr. Protein isolation and quantification are explained 
below. 
2.6.1 Protein isolation 
HFF and HES2-CM were seeded (5 x 105 / well) on 6-well plates and then incubated 
with H2O2 for 1 hr. Subsequently, the cell lysates were extracted by exposing the 
cells to CytoBusterTM Protein extraction reagent (Millipore, 71009; 200 µl/well) which 
was mixed with Protease (Roche), Phosphatase inhibitor (PhosSTOP) cocktails 
(Roche) and Maleimide (Sigma-Aldrich, #129585; 100 mmol/L final concentration) for 
5 mins at 4 °C. The cell lysates were scraped of the culture dish and collected into 
separate 2 ml PP tubes. After centrifugation at 14,000 x g for 5 mins at 4 °C the 
supernatant was collected into new PP tubes to either be used directly for 
immunoblotting or to be stored at -20 °C for further applications and analysis. 
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2.6.2 Protein quantification via Bradford Assay 
Protein concentration of the extracted protein samples was determined by performing 
Bradford protein assay (Bradford 1976). A protein standard curve was analysed after 
loading defined amounts of BSA (0, 1, 2, 4, 8, 16 µg in 50 µl H2O). 2 µl of each of the 
protein samples was diluted with 48 µl H2O and analysed in parallel. All samples 
were analysed in triplicates. 200 µl of 1x Bradford reagent (Roti Quant, K015.3, 
ROTH; diluted in H2O) was added and the samples incubated for 5 mins at RT. 
Sample absorbance was measured at 595 nm in a Flexstation® 3 Multi-mode 
microplate reader (Molecular Devices). The concentration of protein samples were 
analysed and calculated according to the standard curve. 
2.6.3 SDS-PAGE and immunoblotting analysis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed for protein separation according to their molecular weight. 12% SDS-
polyacrylamide gels (Appendix 1) were used. 20 µg of each protein sample was 
mixed with 6x Laemmli Loading Buffer (Appendix 1) together with Maleimide (Sigma-
Aldrich, #129585; 100 mmol/L final concentration) to protect the oxidized states of the 
proteins. The protein samples were denatured at 95 °C for 5 mins. After denaturation, 
30-40 µl of each of the protein samples and 5-10 µl of the Precision PlusTM Protein 
KaleidoscopeTM protein ladder (BioRad) were loaded on the SDS-PAGE gel. The 
system was operated in 1x running buffer (Appendix 1) at 70 V and later the voltage 
was increased to 120 V to separate the protein samples. 
 
The proteins were then transferred electrophoretically from the SDS-PAGE gels to 
polyvinylidene fluoride membranes (PVDF; AmershamTMHybondTMP 0.45) in 1x 
transfer buffer (Appendix 1) at 4 °C for 1 hr at 100 V. The membranes were 
incubated in 10% Roti-blocking buffer (Roth), which was diluted in distilled H2O. 
During incubation, the membranes were placed on a mechanical rocking platform for 
1 hr at RT. The primary antibody (anti-peroxiredoxin) was diluted in TBST buffer 
(Appendix 1; Table 8) and added to the membranes overnight at 4 °C. The next day, 
the membranes were washed 3x with TBST buffer in 10 mins intervals. A secondary 
horse radish peroxidase (HRP)-coupled antibody was added to the membranes and 
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incubated for 1 hr at RT on the rocking platform at the indicated dilution (Table 8). 
Detection of the protein-antibody complex was done by using the chemiluminescent 
reagent Super Signal® West Femto Maximum Sensitive Substrate (Thermo 
Scientific). A ChemDocTM MP Imaging System (BioRad) and Image LabTM Software 
v5.1 (BioRad) were used to visualise and analyse the signals. 
 
List of Antibodies Dilution / amount 














































































- 1 µg/ml 
 
Table 8: List of primary/secondary antibodies and fluorescent conjugates used 
in this study together with the manufacturers (catalogue number) and dilution 
factors. 
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2.7 Generation and analysis of Human Engineered Heart Muscle 
Engineered heart muscle (EHM) is a hydrogel based (collagen) construct that 
consists of cellular and ECM components (Soong et al. 2012, Tiburcy et al. 2011, 
Zimmermann et al. 2002). The EHM used in this study were optimized to exhibit 
properties of postnatal myocardium (Tiburcy et al. 2017). 
2.7.1 Construction and casting of EHMs 
The EHM reconstitution mixture was cast into custom-made circular molds with 
central poles (Figure 11A; (Tiburcy et al. 2014)). The outer and inner diameters of an 




Figure 11: EHM mold and stretcher construct design. (A) Top view of a glass 
culture dish filled with silicon to form 4 circular molds around central Teflon or silicone 
cylinder. (B) Side view of the culture dish with two circular casting molds (outer/inner 
diameter: 10/4 mm). (C-D) Dynamic mechanical silicon stretcher design. Images 
adapted from (Tiburcy et al. 2014). 
 
Casting of EHMs was done on ice and all master mix components (Table 9) were 
kept cold (4 °C), under sterile conditions. All steps were done on ice to prevent 
premature polymerizations. At first, cardiomyocytes and fibroblasts were prepared at 
a ratio of 70:30, respectively and triturated into EHM medium (Appendix 1). To 
prepare the master mix, collagen type I was mixed with 2x RPMI (Appendix 1). The 
A) B)
C) D)
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pH was adjusted by drop wise addition of 0.1 N NaOH. A colour change from yellow 
to pink indicates a pH of ~7.4. The cell suspension was then added to the master mix 
and triturated to ensure homogeneous cell distribution within the EHM mixture. In the 
last step, 450 µl of EHM mixture was added gently into each of the circular molds 
together with the EHM cell mixture and incubated at 37 °C with 5% CO2 for 1 hr to 
facilitate polymerization.  
 
 
Master mix components 
Number of EHMs 
1 x 4 x 8 x 
Bovine Collagen (6.9 mg/mL) 68 µl 271 µl 542 µl 
2x RPMI (Appendix 1) 68 µl 271 µl 542 µl 
0.1 N NaOH 13 µl 53 µl 106 µl 
Cell Suspension (1.45 x 106/EHM) 378 µl 1511 µl 3022 µl 
Total volume 527 µl 2106 µl 4212 µl 
 
Table 9: EHM master mix components. 
 
After the initial polymerization period, serum-free maturation medium (SFMM) with 
TGF-ß1 (5 ng/mL) was added. The medium was changed after 24 hrs. EHMs were 
left to condense for 3 days and then transferred onto flexible mechanical silicon 
stretchers (Figure 11C and 11D) in 24-well plates (Figure 12). EHMs culture was for 









Figure 12: EHM condensation and mechanical (dynamic) loading.(A) EHM 
condensed for 1 hr at 37 °C. (B) Full condensation of EHM 3 days after casting. (C) 
Mechanical loading of EHM on dynamic silicon stretchers in 24-well plates. (Bars: 5 
mm). Images adapted from (Tiburcy et al. 2014). 
2.7.2 Visualisation of redox changes in transgenic EHMs 
To visualize redox changes, EHMs were cast into three groups: 1) wild type (wt) 
EHMs with both non-transgenic HES2-CM and HFF; 2) EHMs with transgenic 
roGFP2-HES2-CM and non-transgenic HFF; and 3) EHM with non-transgenic HFF 
and transgenic roGFP2-HES2-CM. After 20 days of cultivation, EHMs from each 
group were washed with pre-warmed (37 °C) Tyrode’s solution (Appendix 1) and 
transferred onto silicon stretchers fixed on a glass coverslip (VWR, #33386, 25 mm 
Ø). The imaging setup was composed of a polychrome light source (Till Photonics) 
under the control of Visiview Software as previously described (Giovarelli et al. 1995, 
Swain et al. 2016). The EHMs with roGFP2 sensor were excited at 405 nm and 488 
nm and emission was detected via a CCD camera at 510 nm (Figure 10). Signal-to-
noise ratio was measured at 300 ms exposure and images were acquired every 10 
sec. Once a stable baseline 405/488 nm ratio was reached, generally at 300 sec, the 
EHMs were subjected to Tyrode’s solution containing different concentrations of 




 Materials and Methods 
42 
 
excitation, were visualized at 4x magnifications and the mean intensities were used 
to calculate OxDroGP2 (see Section 2.4.1). 
2.7.3 Isometric force measurements 
Isometric force measurement were performed as described previously (Zimmermann 
et al. 2000) in organ baths filled with Tyrode’s solution at 37 °C and perfused with 
carbogen (95% O2, 5% CO2) to stabilize the pH at 7.4. After 20 days of maturation, 
the EHMs were transferred onto hooks of a force transducer suspended in organ 
baths and electrically stimulated at 4 Hz in an electrical field generated by two 
parallel platinum electrodes (5 ms monophasic pulses of 200 mA). First, EHM were 
preloaded to a length with optimal force development (Lmax; Frank-Starling 
mechanism) at 1.8 mmol/L [Ca2+]. This was followed by thorough washing (2x) in 0.2 
mmol/L [Ca2+] containing Tyrode’s solution and finally an exposure to increasing 
concentrations of [Ca2+] (0.2 – 4 mmol/L) to establish a calcium response curve 
(maximal inotropic effect and EC50). At EC50 calcium concentrations (wt EHM, 
0.65±0.06, n=50; roGFP HFF, 0.83±0.12, n=37; roGFP CM, 0.55±0.06, n=31), EHMs 
were exposed to different concentrations of H2O2 (0.1 – 1,000 µmol/L) and DTT (0.01 
– 3 mmol/L) and the maximum and minimum forces were acquired by BMON and 
analysed by AMON Softwares (G. Jaeckel, Hanau). 
2.7.4 EHM dissociation 
EHM dissociation was performed by incubating EHMs in 1 ml collagenase solution 
(Appendix 1) for 1 hr at 37 °C. The collagenase solution together with the dissociated 
parts of EHMs was collected into a PP tube (BD Bioscience) and neutralized with 
Blocking Buffer Solution (Appendix 1); the remaining EHM fragments were incubated 
in Accutase Digestion Solution (Appendix 1) for 30 mins at 37 °C and collected in the 
same PP tube. After complete dissociation, the cell number and viability were 
measured by using a CASY Model TT cell counter. The cell suspension was then 
strained through a 70 µm mesh to remove remaining cell/tissue clumps. 
Subsequently, the cell suspension was either directly used for flow cytometry to 
measure live cells or fixed in cold 70% ethanol or 4% Roti® Histofix at RT for 
immunofluorescence staining.  
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2.7.5 Immunofluorescent staining and low cytometry 
The cell suspension was centrifuged at 300 x g for 5 mins to remove the fixing 
solution. The cells were then incubated in blocking buffer (Appendix 1) for 10 mins on 
ice. The staining and analysis was as described in section 2.1.4.2. 
2.8 Statistics 
Data are presented as arithmetic mean ± SEM. Statistical analysis were performed 
by one-way ANOVA, two-way ANOVA, two-tailed unpaired Student’s t-test with 
indicated post hoc tests using GraphPad Prism v6 (GraphPad Software Inc., San 





3.1 Cloning of pGIPZ- Grx1-roGFP2 
The “Grx1-roGFP2” biosensor (Meyer and Dick 2010) was cloned into the pGIPZ 
backbone for subsequent production of lentivirus particles and transduction to report 
EGSH in cardiomyocytes and fibroblasts. 
3.1.1 Integration of XbaI and NotI cutting sites on CMV-Grx1-roGFP2 
The cytomegalovirus (CMV) promoter together with the biosensor coding sequence 
(Grx1-roGFP2) from the original plasmid (pLPCX-Grx1-roGFP2; kind gift from T. 
Dick, Heidelberg) were ligated (Table 1 in Material and Methods) and the sequence 
size (1,750 base pair) was confirmed by agarose electrophoresis separation (Figure 
13A). 
 
Depending on the size (~1,750 bp), each of the PCR product obtained by the primer 
combinations (A-D) was ligated to TOPO vector. Rapid ligation of the biosensor into 
TOPO vector was performed within 5 min incubation due to rapid ligation of the 3’-A 
overhangs to the PCR product by taq polymerase enzyme. Following overnight (16 
hrs) transformation, white (positive) colonies were picked and the modified plasmid 
was extracted. RE digestion of the plasmids was performed to determine positive 
clones containing the right ligation orientation by gel electrophoresis (Figure 13B). 
Clone A containing the ligation of PCR product (CMV-Grx1-roGPF2) of primer 
combination A (forward F1 and reverse R primers) with TOPO vector, was chosen for 








Figure 13: Schematic view of the subcloning strategy. (A) Representative gel of 
the PCR product for all primer combinations A-D. (B) Schematic diagram of the 
ligation strategy for the insertion of Grx1-roGFP2 into a TOPO vector and verification 
of the insertion in clone A1 by RE digestion (XbaI/NotI). DNA ladder: 1 kb Plus 
(Fermentas). 
3.1.2 Generation of the lentivirus plasmid pGIPZ-Grx1-roGFP2 
Generation of pGIPZ-CMV-Grx1-roGFP2 was performed by replacing the CMV-
turboGFPtag sequence of the pGIPZ backbone with the CMV-Grx1-roGFP2 
sequence. The resulting clones were screened by RE digestion (Figure 14A). 23 out 
of 24 clones were positive for Grx1-roGFP2. Random clones were selected and 




roGFP2 construct into pGIPZ plasmid (Figure 14B). Clone 4 was selected for 
lentivirus production and further glutathione redox measurements. 
 
 
Figure 14: Verification of pGIPZ-CMV-Grx1-roGFP2 cloning. (A) RE digestion 
with XbaI and NotI released the CMV-Grx1-roGFP2 fragment (1,750 bp) from the 
vector backbone (10.3 kb). (B) DNA sequencing of Grx1-roGFP2 fragment confirmed 







3.2 Grx1-roGFP2 expression in TSA cells and lentivirus production 
pGIPZ-Grx1-roGFP2 (clones 4 and 7; Figure 14A), the packaging plasmid psPAX.2 
and the envelope construct pMD2.G were co-transfected into TSA cells. The original 
pGIPZ plasmid containing GFP was used as a positive control for TSA cell 
transfection. After 72 hrs of transfection, TSA cells were visualized for positive GFP 




Figure 15: TSA cells after 72 hrs of transfection. (top) Brightfield; (bottom) GFP 
fluorescence after transfection of pGIPZ-Grx1-ro-GFP2 (clones 4 and 7) and pGIPZ 
plasmids with the lentivirus helper plasmids psPAX.2 and pMD2.G. Scale bar: 200 
µm. 
 
Similar GFP signal intensities suggest similar transfection efficiencies in the pGIPZ 
and pGIPZ-Grx1-roGFP2 (clones 4 and 7) groups. Virus particle containing 





3.2.1 Lentivirus transduction of HFF and HES2-CM 
HFFs were transduced with lentivirus containing the biosensor from both clone 4 and 




Figure 16: HFFs after transduction. (top) Brightfield; (bottom) GFP fluorescence 
after transduction with lentivirus harvested from TSA transfected with pGIPZ-Grx1-
roGFP2 clone 4 and 7 as well as pGIPZ. Scale bar: 200 µm. 
 
According to previously established killing curves (Soong, PhD thesis) positively 
transduced HFFs were selected using 1 µg/ml puromycin for 4 days. Lentivirus 
derived from clone 4 showed a stronger GFP intensity and transduction efficiency 
than clone 7. As such, all the following experiments were performed using construct 
4. Transduction of HFFs and HES2-CMs by the purified lentivirus, resulted in the 
expression of GFP in each cell type (Figure 17A, 18A). Transduction efficiency was 








Figure 17: Transduction efficiency in HFFs. (A) (left) Brightfield; (right) GFP 
fluorescence after lentiviral transduction of HFF with biosensor Grx1-roGFP2. Scale 







Figure 18: Transduction efficiency in HES2-CMs. (A) (left) Brightfield; (right) GFP 
fluorescence after lentiviral transduction of HES2-CM with biosensor Grx1-roGFP2. 
Scale bar: 200 µm. (B) Transfection efficiency analysed by flow cytometry (p<0.05, 
Student’s t-test). 
3.3 Monolayer glutathione redox measurements 
Genetically encoded redox biosensors allow for quantification of redox couples inside 
the cell. In this study, the glutathione redox sensor Grx1-roGFP2 was expressed in 
the cytosol. By titration of H2O2, DA and DTT it was possible to quantify the ratio of 
the reduced and oxidized forms of the glutathione couple [GSH:GSSG] in HFF and 
HES2-CM. Fluorescence changes were analysed ratiometrically from regions of 









Figure 19: Cell-specific analysis of the glutathione redox sensor in HFF and 
HES2-CM. ROI: region of interest for fluorescence intensity measurements. Scale 
bars: 40 and 20 µm in HFF and HES2-CM, respectively. 
3.3.1 Oxidative challenge with H2O2 
Exposure to H2O2 causes disulfide bond formation between Cys147 and Cys204 in 
the glutathione protein (GSH + GSH  GSSG). This change promotes the 
protonation of the roGFP2 chromophore, leading to increased fluorescence emission 
under 405 nm versus 490 nm excitation. Treatment with DTT has the reverse 
function (GSSG  GSH + GSH).  
 
Grx1-roGFP2 transduced HFFs (Figure 20) and HES2-CMs (Figure 21) were treated 
with different concentrations of H2O2 (0.1 – 1,000 µmol/L). Interestingly, a 
concentration dependent response was observed in HFF whereas HES2-CM 
demonstrated an all or nothing response with maximal effects at 100 µmol/L in HFF 








Figure 20: Live imaging of glutathione oxidation in HFFs under H2O2 challenge. 
(A) Changes in the ratiometric fluorescence signal of the Grx1-roGFP2 in HFF in 
response to H2O2 at the indicated concentrations as a function of time (Ro= 405/490 
nm excited signals at baseline); H2O2 was added at 60 sec of stable baseline 
recordings. (B) Maximal ratiometric signal increase at the indicated H2O2 
concentrations. 19-43 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) 
ANOVA followed by Dunnett’s post hoc test. 
 
 
Figure 21: Live imaging of glutathione oxidation in HES2-CMs under H2O2 
challenge. (A) Changes in the ratiometric fluorescence signal of the Grx1-roGFP2 in 
HES2-CM in response to H2O2 at the indicated concentrations as a function of time 
(Ro= 405/490 nm excited signals at baseline); H2O2 was added at 180 sec of stable 
baseline recordings. (B) Maximal ratiometric signal increase at the indicated H2O2 
concentrations. 46-71 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) 





The onset of glutathione oxidation was similar in HFF (Figure 22A) and HES2-CM 




Figure 22: Differences in glutathione oxidation kinetics in HFF and HES2-CM. 
Time required for half maximum reporter signal (t50) increase in HFF (n=27-41); A) 
and HES2-CM (n=39-47); B) cultures. *p<0.05 vs. 10 µmol/L H2O2 by one-way 
ANOVA followed by Tukey’s post hoc test. 
3.3.2 Response of HFF and HES2-CM to DA 
Diamide (DA) is a thiol group oxidant that oxidizes the thiol groups of roGFP2 directly 
into disulfides. Thus it does not depend on the availability of glutathione in the cell 
(Swain et al. 2016). Hence, DA stimulation allows for the determination of the 
maximal roGFP2 signal change obtainable under an oxidative challenge. HFFs and 
HES2-CMs expressing the Grx1-roGFP2 were exposed to different concentrations of 
DA (1 - 1,000 µmol/L). Similar as for H2O2 maximal oxidation under DA was achieved 
at lower concentrations in HES2-CM as compared to HFF (0.1 vs 1 mmol/L) (Figure 
23 and 24). Time to maximal reporter signal was similarly DA concentration 







Figure 23: Live imaging of glutathione oxidation in HFFs under DA challenge. 
(A) Changes in the ratiometric fluorescence signal of the Grx1-roGFP2 in HFF in 
response to DA at the indicated concentrations as a function of time (Ro= 405/490 
nm excited signals at baseline); DA was added at 60 sec of stable baseline 
recordings. (B) Maximal ratiometric signal increase at the indicated DA 
concentrations. 26-60 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) 
ANOVA followed by Dunnett’s post hoc test.  
 
 
Figure 24: Live imaging of glutathione oxidation in HES2-CMs under DA 
challenge. (A) Changes in the ratiometric fluorescence signal of the Grx1-roGFP2 in 
HES2-CM in response to DA at the indicated concentrations as a function of time 
(Ro= 405/490 nm excited signals at baseline); DA was added at 180 sec of stable 
baseline recordings. (B) Maximal ratiometric signal increase at the indicated DA 
concentrations. 7-9 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) 





The time required for biosensor oxidation in HFFs is similar and independent of the 
DA concentrations (Figure 25A). Interestingly, HES2-CM showed a DA concentration 
dependent acceleration in DA mediated oxidation with slower and faster kinetics at 
10 and 1,000 µmol/L DA, respectively (Figure 25B). 
.   
 
 
Figure 25: Differences in biosensor oxidation kinetics in HFF and HES2-CM. 
Time required for half maximum reporter signal (t50) increase in HFF (n=12-55); A) 
and HES2-CM (n=7-15); B) cultures. *p<0.05 vs. 10 µmol/L and 100 µmol/L DA by 
one-way ANOVA followed by Tukey’s post hoc test. 
 
3.3.3 Response of HFF and HES2-CM to DTT 
To investigate the reducing properties of the biosensor Grx1-roGFP2, trangenic HFFs 
and HES2-CMs were exposed to various concentrations (0.01 - 1.0 mmol/L) of 
reducing agent DTT (Figures 26 and 27). In contrast to the findings in response to 
oxidation with H2O2 and DA there was a clear concentration dependency in HFF and 
HES2-CM. However, HFF demonstrated a much stronger signal reduction by 1 








Figure 26: Live imaging of glutathione oxidation in HFF under DTT challenge. 
(A) Changes in the ratiometric fluorescence signal of the Grx1-roGFP2 in HFF in 
response to DTT at the indicated concentrations as a function of time (Ro= 405/490 
nm excited signals at baseline); DTT was added at 180 sec of stable baseline 
recordings. (B) Maximal ratiometric signal decrease at the indicated DTT 
concentrations. 21-37 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) 




Figure 27: Live imaging of glutathione oxidation in HES2-CMs under DTT 
challenge. (A) Changes in the ratiometric fluorescence signal of the Grx1-roGFP2 in 
HES2-CM in response to DTT at the indicated concentrations as a function of time 
(Ro= 405/490 nm excited signals at baseline); DTT was added at 180 sec of stable 
baseline recordings. (B) Maximal ratiometric signal decrease at the indicated DTT 
concentrations. 46-85 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) 





Another obvious difference was the markedly slower kinetics of Grx1-roGFP2 
reduction (21 ± 0.9 ms in HFF vs.  83 ± 3.1 ms in HES2-CM at 1 mmol/L DTT; n= 
28/58; Figure 28).  
 
 
Figure 28: Differences in glutathione reduction kinetics in HFF and HES2-CM. 
Time required for half maximum reporter signal (t50) decrease in HFF (n= 21-37); A) 
and HES2-CM (n= 40-62); B) cultures; *p<0.05 vs. 0.01 mmol/L DTT by one-way 
ANOVA followed by Tukey’s post hoc test. 
3.3.4 Calculation of the glutathione redox potential 
Glutathione redox potential (EGSH) was calculated for both cell types by using the 
Nernst Equation (Section 2.4.1, equation (3) Materials and Methods). The 
calculations were based on the OxDroGFP2 of the maximum response for oxidation 
(H2O2 and DA) and the maximum response for reduction (DTT). HES2-CMs 
demonstrated a significantly more reduced EGSH compared to HFFs (Table 10). There 
was no difference in DA-DTT and H2O2-DTT signal range based calculation of EGSH, 











Redox potential Cell type 
HES2-CM HFF 
Diamide-DTT -289 ± 1.3 mV* 
(13) 
-270 ± 1.1 mV 
(18) 
H2O2-DTT -289 ± 1.3 mV* 
(56) 
-269 ± 1.6 mV 
(18) 
 
Table 10: EGSH of the glutathione sensor in HFFs and HES2-CMs. Number of 
analyzed cells is shown inside the parentheses. *p<0.05 HES2-CM vs. HFF by 
unpaired, two-tailed Student’s t-test. 
3.3.5 Glutathione redox changes upon cumulative redox challenge 
In addition to the effects of bolus administration of H2O2 and DTT, responses to 
cumulative additions were analysed in HFFs (Figure 29).  These analyses suggest a 
good dynamic range of the Grx1-roGFP2 sensor with the possibility to sense 




Figure 29: Assessment of the dynamic range of the Grx1-roGFP2 sensor. 






3.4 Grx1-roGFP2 responses to angiotensin II and inotropes 
Angiotensin II has been demonstrated to increase ROS/roGFP2 signal in murine 
heart preparations (Swain et al. 2016). In HFF and HES2-CM there was a distinct 
response to Angiotensin II with at all a mild reductive effect in HFFs at 100 nmol/L 
(Figure 30), but a strong oxidative effect in HES2-CM already at low (0.1 nmol/L) 
angiotensin II concentrations (Figure 31); notably, there appeared to be a 




Figure 30: Visualization of glutathione redox states under angiotensin II 
stimulation in HFF. (A) Changes in the ratiometric fluorescence signal of the Grx1-
roGFP2 in HFF in response to angiotensin II (AngII) at the indicated concentrations 
as a function of time (Ro= 405/490 nm excited signals at baseline); angiotensin II was 
added at 300 sec of stable baseline recordings and (B) Maximal ratiometric signal 
increase at the indicated angiotensin II (AngII) concentrations. 42-68 cells/group; 











Figure 31: Visualization of glutathione redox states under angiotensin II 
stimulation in HES2-CM. (A) Changes in the ratiometric fluorescence signal of the 
Grx1-roGFP2 in HES2-CM in response to angiotensin II (AngII) at the indicated 
concentrations as a function of time (Ro= 405/490 nm excited signals at baseline); 
angiotensin was added at 300 sec of stable baseline recordings and (B) Maximal 
ratiometric signal increase at the indicated angiotensin II (AngII) concentrations. 31-
71 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) ANOVA followed by 
Dunnett’s post hoc test. 
 
Next, the cells were exposed to increasing concentrations of the calcium-sensitizer 
levosimendan (LEVO; 0.01 - 10 µmol/L). Similarly as observed for angiotensin II, 
there was an effect in both HES2-CM (Figure 32) and HFF (Figure 33). The apparent 
increase in oxidation in the Ctrl group appeared to be an effect of the solvent (DMSO) 
and may have to be considered when interpreting the data. In all the experiments 
with levosimendan (LEVO) and omecamtiv mecarbil (OME), the Ctrl group includes 
1% DMSO, whereas the sample dilutions (0.01 - 10 µmol/L) contain less DMSO 
































Figure 32: Visualization of glutathione redox states under levosimendan 
treatment in HFF. (A) Changes in the ratiometric fluorescence signal of the Grx1-
roGFP2 in HFF in response to levosimendan (LEVO) at the indicated concentrations 
as a function of time (Ro= 405/490 nm excited signals at baseline); levosimendan 
was added at 300 sec of stable baseline recordings and (B) Maximal ratiometric 
signal increase at the indicated levosimendan (LEVO) concentrations (17-41 
cells/group). 
 
Surprisingly, the sample dilutions of levosimendan did not show any significant 
difference on oxidizing effect when compared to the Ctrl group in HFFs (Figure 32). 
However, Ctrl group in HES2-CMs treated with levosimendan showed a more 













Figure 33: Visualization of glutathione redox states under levosimendan 
treatment in HES2-CM. (A) Changes in the ratiometric fluorescence signal of the 
Grx1-roGFP2 in HES2-CM in response to levosimendan (LEVO) at the indicated 
concentrations as a function of time (Ro= 405/490 nm excited signals at baseline); 
levosimendan was added at 300 sec of stable baseline recordings and (B) Maximal 
ratiometric signal increase at the indicated levosimendan (LEVO) concentrations. 9-
21 cells/group; *p<0.05 vs. Ctrl by two-way (A) and one-way (B) ANOVA followed by 
Dunnett’s post hoc test. 
 
Finally, the cells were exposed to omecamtiv mercabil (OME; 0.01 - 10 µmol/L), a 
cardiac myosin activator. In contrast to AngII and LEVO, a reduced Grx1-roGFP2 
signal was observed under OME stimulation only in HES2-CM without a clear 
concentration dependency (Figure 35). Similar as for the LEVO experiments, the 
oxidative effects of DMSO have to be considered, which appeared more pronounced 








Figure 34: Visualization of glutathione redox states under omecamtiv mecarbil 
treatment in HFF. (A) Changes in the ratiometric fluorescence signal of the Grx1-
roGFP2 in HFF in response to omecamtiv mecarbil (OME) at the indicated 
concentrations as a function of time (Ro= 405/490 nm excited signals at baseline); 
omecamtiv mecarbil was added at 300 sec of stable baseline recordings and (B) 
Maximal ratiometric signal increase at the indicated omecamtiv mecarbil (OME) 
concentrations. 13-22 cells/group; *p<0.05 vs Ctrl by two-way (A) and one-way (B) 
ANOVA followed by Dunnett’s post hoc test. 
 
 
Figure 35: Visualization of glutathione redox states under omecamtiv mecarbil 
treatment in HES2-CM. (A) Changes in the ratiometric fluorescence signal of the 
Grx1-roGFP2 in HES2-CM in response to omecamtiv mecarbil (OME) at the 
indicated concentrations as a function of time (Ro= 405/490 nm excited signals at 
baseline); omecamtiv mecarbil was added at 300 sec of stable baseline recordings 
and (B) Maximal ratiometric signal increase at the indicated omecamtiv mecarbil 




3.5 Detection of peroxiredoxin oxidation 
Exposure of cells to oxidative stress (e.g., by exposure to H2O2) is anticipated to 
result in the oxidation of cysteines (Cys-SH) in a wide array of proteins, including 
peroxiredoxin (Prx). Cysteines in Prx are reversibly oxidized to sulfenic acid groups (-
SOH) and irreversibly to sulfinic (-SO2H) or sulfonic acid groups (-SO3H). Immunoblot 
detection of periodoxin-SO3 (Table 8) confirmed that H2O2 at the above as oxidatively 
effective identified concentrations (100 - 1,000 µmol/L) in HFF and HES2-CM indeed 
resulted in the anticipated oxidation of periodoxin (Figure 36). Interestingly, Grx1-
roGFP2 sensor appeared 10-fold more sensitive as to the detection of oxidation with 




Figure 36: Confirmation of peroxiredoxin oxidation in HFFs and HES2-CMs 
upon H2O2 exposure. Protein lysates were prepared 1 hr after exposure to the 
indicated H2O2 concentration. Protein oxidation was stabilized with maleimide. 
Representative Immunoblots and analyses of all obtained data (Prx-SO3 signals were 
corrected to GAPDH signals). (A-B) data from HFF cultures (n=9/group); (C-D) data 
from HES2-CM cultures (n=5-6/group). *p<0.05 vs. Ctrl by one-way ANOVA followed 




3.6 Redox sensing in engineered heart muscle 
To assess whether changes of the glutathione redox state in HFFs and HES2-CMs 
can be determined in a multicellular human tissue context, EHM (Tiburcy et al. 2017) 
were constructed from distinctly labelled (Grx1-roGFP2) mixtures of HFF and HES2-





Figure 37: Expression and monitoring of the glutathione redox sensor in EHM. 
(A) EHM with Grx1-roGFP2 glutathione redox sensor expressed in roGFP HFF (B) 
Zoom in on a ROI for roGFP2 detection in EHM (left); control EHM without the 
expression of Grx1-roGFP2 (right). Scale bar: 200 µm. 
3.6.1 Glutathione redox measurements in EHM 
EHM with either HFF or HES2-CM expressing Grx1-roGFP2 were exposed to H2O2 
and DTT at maximally effective concentrations (1 mmol/L; Figure 38). These 
experiments confirmed the utility of the Grx1-roGFP2 sensor in multicellular human 
tissue preparations and in addition demonstrated the concept of cell type specific 
redox sensing in HFF (Figure 38A) and HES2-CM (Figure 38B). Oxidative challenge 









Figure 38: Cell type specific visualization of redox alteration in engineered 
human myocardium. Changes in the ratiometric fluorescence signal of the Grx1-
roGFP2 in (A) HFF (1-2 EHM/group) and (B) HES2-CM (2-4 EHM/group) in response 
to H2O2 (1 mmol/L) and DTT (1 mmol/L) as a function of time (Ro= 405/490 nm 
excited signals at baseline); H2O2 or DTT were added as indicated at 300 sec of 






3.6.2 Contraction force measurement 
EHM were developed under biomimetic conditions to obtain functional properties of 
bona fide myocardium, which can be measured under defined isometric conditions 
(Figure 39) (Tiburcy et al. 2017). Inotropic properties of EHM were analysed under 
exposure to increasing extracellular calcium concentrations. This confirmed similar 





Figure 39: Assessment of potential Grx1-roGFP2 toxicity in EHM. (A) EHM 
during culture on flexible silicone poles to facilitate auxotonic contractions. (B) EHM 
suspended in an organ bath filled with Tyrode’s solution at 37 °C for isometric force 
measurements under electrical field stimulation (1.5 Hz). Force of contraction (FOC) 
under increasing extracellular calcium concentrations as indicated in EHM comprising 





































Finally, concentration response curves for H2O2 and DTT were analysed to determine 
whether oxidative or reductive challenges would affect human EHM contractility. This 
set of experiments demonstrated surprisingly little acute effects at a wide range of 
concentrations tested (Figure 40). However at highest oxidative (H2O2: 1 mmol/L) 
and reductive challenge (DTT: 3 mmol/L) contractile function was reduced and 




Figure 40: Functional consequences of oxidation and reduction in EHM 
contractility. EHM were exposed to increasing concentrations of H2O2 (A; n= 9-
15/group) or DTT (B; n= 6-19/group) as indicated. FOC was assessed isometrically 
under electrical field stimulation (1.5 Hz) at EC50 calcium concentrations (individually 
determined prior to exposure to H2O2 or DTT). EHM from all tested groups 
demonstrated similar responses, confirming that lentiviral transduction with Grx1-
















Redox signaling affects the heart both physiologically (e.g., cell growth, 
differentiation, excitation-contraction coupling) and pathologically (e.g., fibrosis, 
cardiac remodeling, hypertrophy) (Burgoyne et al. 2012, Santos et al. 2011). Cells 
are equipped with redox-stress defense mechanisms that include endogenous 
antioxidants (e.g., glutathione, glutathione peroxidase, thioredoxin, peroxiredoxin) 
(Hafstad et al. 2013, Santos et al. 2011). Therapeutic application of compounds with 
antioxidant activity has been proposed as an approach to protect the heart, with 
however so far limited success. A key challenge to the field is to determine the 
mechanisms underlying the fine-tuning of the redox status in cells and its subcellular 
compartments. The application of redox assays/sensors promises for detailed insight 
into qualitative and quantitative changes of the redox state of the cell. Until recently, 
most studies have utilized a variety of redox sensitive dyes, such as 
dichlorodihydrofluorescein diacetate, amplex red, and dihydrorhodamine (Forkink et 
al. 2010, Griendling et al. 2016, Meyer and Dick 2010) to monitor both ROS in and 
redox states of cells. The recent advent of genetically encoded redox sensors 
promises to advance the field markedly because of the possibility to target sensors to 
subcellular compartments (Swain et al. 2016) or cell types, as demonstrated in this 
thesis. 
 
The following main observation could be made: 
 
1) Human fibroblasts and cardiomyocytes can be stably transduced with the 
cytosolic glutathione redox sensor Grx1-roGFP2 without signs for transgene 
toxicity. 
 
2) Cardiomyocytes are more sensitive to oxidation and less reactive to reduction 






3) This may at least in part be explained by the more reduced glutathione redox 
potential in cardiomyocytes compared to fibroblasts. 
 
4) Fibroblasts as compared to cardiomyocytes displayed a wider range in redox 
state alterations. 
 
5) Fibroblasts show faster responses to oxidative and reductive challenges 
compared to cardiomyocytes.  
 
6) Assessment of redox alterations under pharmacological stimulation was 
confounded by oxidizing effects of DMSO.  
 
7) Glutathione redox sensing can be performed in a cell type specific manner in 
EHM and thus may allow dissecting the “redox-interplay” between different cell 
types in a tissue context. 
 
Fibroblast from human foreskin and cardiomyocytes derived from the human 
embryonic stem cell line HES2 were utilized as surrogates for the most abundant cell 
types of the heart. The suitability of these cells to model human heart function was 
recently demonstrated (Tiburcy et al. 2017).  
4.1 Tools for redox quantification in living cells 
Monitoring of redox alteration in cells and tissue requires tools for the robust and 
quantitative reporting of the dynamic changes in cellular redox states. The most 
promising tools to monitor cellular redox changes dynamically, in real time and 
compartment specific appear to be biological sensors genetically integrated into cells 
of interest (Lukyanov and Belousov 2014, Meyer and Dick 2010). In this study, we 
utilized the genetically encoded glutathione redox sensor Grx1-roGFP2, which 
detects redox changes of the GSH:GSSG couple in a quantitative manner in real 
time. Modifications of the Grx1-roGFP2 sensor have been shown to also allow for 
subcellular targeting of the redox sensor (Swain et al. 2016). This study identified 
differences in the cytosol and mitochondria of murine cardiomyocytes. In this thesis, 




transducing the cytosolic Grx1-roGFP2 sensor into cardiomyocytes and fibroblasts. 
Human embryonic stem (HES) cell-derived cardiomyocytes and human foreskin 
fibroblasts were chosen because of their accessibility and the finding that these cell 
types can be reconstituted to myocardium with structural, molecular, and functional 
properties of the postnatal human heart (Tiburcy et al. 2017). In fact, human foreskin 
and adult heart derived fibroblasts are similarly supportive to heart muscle 
reconstitution in vitro (unpublished data). Lentiviral transduction was chosen in a first 
attempt to validate the concept of Grx1-roGFP2 expression in human cardiomyocytes 
and fibroblasts cells. The need for repeated transduction especially in HES-derived 
cells makes this a tedious approach, which will have to be replaced by the stable 
introduction of the reporters by homologous recombination. In addition, silencing and 
incomplete labelling of the cells of interest is an issue that can be circumvented with 
for example TALEN or CRISPR mediated integration of target sequences in defined 
genomic loci such as the AAVS1 site (Mussolino et al. 2014). Despite these caveats 
it was possible to establish proof-of-concept for glutathione redox potential sensing in 
human heart cells. Validation experiments with oxidizing (H2O2, DA) and reducing 
(DTT) compounds confirmed the principle utility of the Grx1-roGFP2 sensor in human 
cardiomyocytes and fibroblasts. Some of the observed variability may be contributed 
to variable transduction and activity of the Grx1-roGFP2 sensor.   
 
Another robust way to analyze cellular oxidation is by the investigation of 
characteristic protein modifications under oxidative stimulation. For example, 
effective oxidation of peroxiredoxin by H2O2 should lead to its sulfonylation (-SO3) 
(Sobotta et al. 2013), which can be detected by Prx-SO3 specific antibodies. 
Immunoblots confirmed that H2O2 at the chosen concentration range would indeed 
result in oxidation of Prx with an apparent H2O2 concentration dependent effect at 10 
- 1,000 µmol/L H2O2.  
 
4.2 Cell type specific glutathione redox responses 
Both HFFs and HES2-CMs demonstrated a concentration dependent oxidizing and 







Parameter HES2-CM (n) HFF (n) 
H2O2 
EC50 2.6 ± 2.2 µmol/L (46-70) 10.5 ± 1.2 µmol/L (19-43) 
R/Ro (max) +56 ± 4% (57) +78 ± 7% (41) 
t50 
10 µmol/L = 26 ± 1 ms (45) 
100 µmol/L = 26 ± 1 ms (39)    
1,000 µmol/L  = 22 ± 2 ms (39) 
10 µmol/L = 30 ± 3 ms (27)        
100 µmol/L = 6 ± 0.3 ms (41)      
1,000 µmol/L = 5 ± 0.3 ms (41) 
DA 
EC50 16.1 ± 1.4 µmol/L (7-19) 40.7 ± 1.2 µmol/L (42-60) 
R/Ro (max) +57 ± 4% (14) +153 ± 4% (48) 
t50 
10 µmol/L = 49 ± 4 ms (55)                  
100 µmol/L = 36 ± 2 ms (39)    
1,000 µmol/L  = 9 ± 1 ms (23) 
10 µmol/L = 27 ± 1 ms (7)                 
100 µmol/L = 28 ± 3 ms (13)   
1,000 µmol/L = 25 ± 1 ms (15) 
DTT 
EC50 0.2 ± 0.1 mmol/L (46-85) 0.03 ± 0.01 mmol/L (28-45) 
R/Ro (max) -22 ± 1% (58) -64 ± 2% (28) 
t50 
0.01 mmol/L = 131 ± 16 ms (62)        
0.1 mmol/L = 115 ±11 ms (40)    
1 mmol/L  = 83 ± 3 ms (58) 
0.01 mmol/L = 42 ± 4 ms (21)        
0.1 mmol/L = 31 ± 1 ms (37)           
1 mmol/L  = 28 ± 1 ms (28) 
EGSH H2O2-DTT -289 ± 1 mV (56) -269 ± 2 mV (18) 
 
Table 11: Summary of Grx1-roGFP2 sensor activites in HES2-CM and HFF.  
n = numbers of cells analysed. 
 
The more reduced EGSH in cardiomyocytes was a particularly interesting observation 
and has to be considered when interpreting the observed differences in the 
responses to oxidative and reductive challenges. The response range to oxidative 
and reductive stimulation with H2O2 and DTT, respectively, was for both cell types 10 
- 1,000 µmol/L and 0.01 – 1 mmol/L. HES2-CM showed a markedly higher sensitivity 
to oxidation (refer to EC50
 in Table 11) with at the same time a clearly smaller 




demonstrated a ΔR/R0 differences of ~80% vs. ~140% in fibroblasts (absolute % 
change). Another interesting observation was the apparent roGFP-oxidation reserve 
in fibroblasts, which was evidenced by the lower R/R0 signal change under maximal 
H2O2 (~80%) vs. DA (~150%).  
 
Fibroblasts appear to exhibit a particular high expression in NOX4 (RNA-sequencing 
data in (Tiburcy et al. 2017)). NOX4 is constitutively active and H2O2 producing 
(Kuroda et al. 2010) and moreover directly activated by H2O2 mediated oxidation 
(Colston et al. 2005). This suggests a more extensive oxidant load in fibroblasts and 
thus may on the one hand explain the difference in EGSH (Table 11) and the wider 
range in particular of oxidative changes of the redox state. The difference in 
oxidation/reduction kinetics (t50) was a surprising observation and may argue for 
differences in cellular uptake or membrane permeability of H2O2. There is a steep 
gradient of H2O2 between extra- and intracellular compartments with a 100-fold 
higher concentration outside vs. inside the cell, in addition there are differences in 
H2O2 in the different subcellular compartments (Sies 2017). The difference in t50 
reported in this thesis requires more detailed investigations of differences in 
transmembranous H2O2 gradients as well as subcellular targets in cardiomyocytes 
and fibroblasts. The recent demonstration of cytosol and mitochondria targeting of 
the Grx1-roGFP2 sensor is particularly interesting in this context (Swain et al. 2016).  
 
4.3 Cell type specific redox responses to angiotensin II and drugs 
Another aspect of this study was to investigate cell type redox responses upon 
stimulation with angiotensin II and inotropic drugs. From previous studies, stimulation 
with angiotensin II, the key effector of rennin angiotensin system, is known to be 
involved in ROS production pathways by stimulating membrane bound NAD(P)H 
oxidase (Dikalov and Nazarewicz 2013, Griendling et al. 1994, Vazquez-Medina et al. 
2013). In our experiments, HFFs did not exhibit obvious redox changes over the 
whole range of angiotensin II concentrations tested; surprisingly, a reductive effect 
was observed under 100 nmol/L angiotensin II. This is in contrast to the study 
conducted by Sano et al. and Swain et al. They demonstrated ROS production and 




2001, Swain et al. 2016). HES2-CMs showed however some oxidative effects at a 
low angiotensin concentration (0.1 nmol/L). These results are surprising and 
somewhat inconsistent. Stable expression of Grx1-roGFP2 in every cell of interest 
with a similar expression level may help to further clarify these apparently discrepant 
findings. Collectively, these data suggest that assessments of oxidation and 
reduction would benefit from cell-type specific analyses.  
 
In an attempt to study oxidative and reductive drug effects, levosimendan and 
omecamtiv mecarbil were applied to HES2-CM and HFF. These cardioactive 
inotropes are applied in acute heart failure with cardioprotective effects reported for 
levosimendan (via activation of the mitochondrial ATP-sensitive K+-channels) and no 
effect on myocardial oxygen consumption reported for omecamtiv mecarbil (Farmakis 
et al. 2016, Meijs et al. 2012). There was no obvious effect of LEVO and OME in 
cardiomyocyte or fibroblasts oxidation. However, these experiments appeared to be 
severely confounded oxidizing effects of the solvent DMSO. A refinement of the study 
protocol (avoidance of DMSO) is needed to ensure the assessment of drug specific 
effects and confirm the present findings of no effects of LEVO and OME on the redox 
state of cardiomyocytes and fibroblasts. 
4.4 Redox sensing in a heart muscle tissue context 
Up to this point, we discussed results and analysis that were performed in monolayer 
cardiomyocytes and fibroblasts. Cellular measurements provide information 
regarding compound effects and pathways involved in redox changes in specific cell 
cultures. However, investigations in a cardiac muscle model that mimic the 
microenvironment of the heart tissue are physiologically more relevant than 
monolayer cell culture. Furthermore, in a tissue context the interaction between cells 
plays a key role in the investigation of drug effects on redox homeostasis in a cardiac 
tissue.  EHMs exhibit a higher degree of maturity as compared to monolayer cultures 
(resemble an embryonic phenotype); in fact, they reflect in many structural, molecular 
and functional parameters properties of the postnatal human heart (Tiburcy et al. 
2017). By genetically modifying the two most abundant heart cell types and mixing 
them in a defined context, it became possible to define response to redox challenges 




responded in EHM to the bolus of H2O2 and DTT both optically and functionally.  
Stimulation of human EHMs with oxidizing and reducing agents confirmed that we 
were able to detect redox changes occurring within the tissue. Interestingly, 
contractile properties were deteriorated under maximal oxidation and appeared to be 
enhanced under maximal reduction with H2O2 and DTT, respectively. These results 
fit well with previous data showing that redox alterations affect signaling pathways 
(eg. Ca2+/calmodulin-dependent kinase II; CAMKII or cAMP-dependent protein 
kinase; PKA) important in contractility and could bring cardiomyocyte to death 
(Santos et al. 2016).  
 
These studies will be extended in the future to study the interplay between the 
different cardiac cell species and their specific responses to environmental, 
biomechanical, and pharmacological stimuli. In addition, a link to signaling pathways 
will need to be established and assessments of acute vs chronic effects will need to 
be performed. A potential caveat is the thickness of engineered tissue (~ 1 mm) and 
the intra-tissue distance between cells (from direct contact to several 100 µm), which 
may limit cell-cell communication via highly reactive and thus instable oxidants. 
However, effects of oxidation (intracellular or extracellular) of secreted proteins, such 
as extracellular matrix proteins or growth factors, could be studied and may provide 
relevant information on redox-mediated tissue homeostasis. Alternative technologies 
for intra-tissue assessment of oxidation were recently developed (Fujikawa et al. 
2016) and rely on the arrest of the redox state of the roGFP-biosensor by the 
membrane-permeable thiol-alkylating agent (NEM). First experiments in human 
EHMs suggest that this method would indeed be applicable to study the redox state 
histologically. This together with the possibility for in tissue fluorescence analyses by 
confocal (~50 µm penetration depth) and 2-photon (~200 µm) microscopy should 
allow for comprehensive in tissue phenotyping of redox mechanisms and their 
association with heart muscle function.  
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5. Summary and outlook 
 
This study introduces the use of the glutathione redox sensor Grx1-roGFP2 as a tool 
to monitor responses to oxidative and reductive challenges in a human heart muscle 
specific context. Redox challenges are considered key contributors to physiological 
and pathological processes in the heart. In addition, pharmacological interventions 
often influence the cellular redox state. With the introduction of a human Grx1-
roGFP2 engineered heart muscle (EHM) model we anticipate to be able to contribute 
to the definition of mechanisms underlying wanted and unwanted drug effects as well 
as cardiac disease progression. A key observation of this study was the finding of a 
differential glutathione redox potential in cardiomyocyte and fibroblasts. Thus, drugs 
with oxidant and antioxidant activity may elicit sometimes even mechanistically 
opposing functions in the different myocardial cell compartments. Future studies will 
investigate this finding in more detail and take advantage of the possibility to 
reconstitute EHM with defined cell types with or without a genetically encoded redox 
sensor. Targeting subcellular compartments in a cell type specific context will further 
open experimental possibilities to decipher redox mechanisms and may eventually 
contribute to the development of cell and cell compartment targeted interventions for 
the treatment of heart failure.  





Reagents for cloning 
 
LB-medium 
10 g  Bacto-Tryptone 
5 g  Bacto Yeast Extract 
10 g  NaCl 
All the components were dissolved and filled up to 1 L of dH2O. pH was adjusted to 
7.4. The medium was stored at 4 °C for up to 3 weeks. 
 
Ampicillin  
To prepare a stock of 100 mg/mL 200 mg were dissolved in 2 ml of dH2O. The stock 
solution was aliquoted in 500 µl and stored at –20 °C. 
 
LB-agarose plate (with ampicillin resistance) 
7.5 g  Agar  
500 ml LB-medium 
500 µl  Ampicillin stock (100 mg/mL) 
The agar was dissolved in LB-medium and autoclaved. After cooling down to 50 °C, 
ampicillin stock was added and the solution was poured into 10 cm petri dishes. 
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Reagents for DNA gel electrophoresis  
 
50x TAE 
242 g  Tris-Base 
100 ml EDTA (0.5 mol/L; pH 8.0) 
57.1 ml Glacial acetic acid 
The ingredients were dissolved in 800 ml of dH2O, adjusted pH at 8.5 and then filled 
up to 1 L of dH2O. For gel electrophoresis, 1x TAE buffer was used (1:50 dilution). 
 
6x DNA loading buffer (2 colors) 
75 mg  Bromophenol-Blue 
25 mg  Xylene cyanol 
100 ml Glycerol (30%) 
 
1 % agarose gel 
1 g of Agarose UltraPureTM powder (AppliChem) was boiled in 100 ml TAE buffer 
until the powder was completely dissolved. After cooling, 0.2 µg/ml ethidium bromide 
(EtBR; Sigma-Aldrich) was added into the gel solution, following by a gentle swirl. 
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Reagents and media for cell culture 
 
Activin A stock solution 
(Manufacturer’s protocol) 
To prepare a stock solution of 10 µg/ml dissolve activin A (Recombinant 
Human/Mouse/Rat Activin A protein; R&D Systems #338-AC) in 1x PBS with 0.1 % 
human recombinant serum albumin (HAS) (Sigma-Aldrich #A9731). Aliquots were 
stored in -20 °C. 
 
BMP-4 stock solution 
(Manufacturer’s protocol) 
To prepare a stock solution of 10 µg/ml dissolve BMP-4 (Recombinant Human BMP-
4; Sigma-Aldrich #314-BP) in 1x PBS with 0.1% HSA (Sigma-Aldrich #A9731). 
Aliquots were stored in -20 °C. 
 
IWP-4 stock solution 
(Manufacturer’s protocol) 
To prepare a stock solution of 5 mmol/L dissolve IWP-4 (Stemolecule™ Wnt inhibitor 
IWP-4; Stemgent #04-0036) in DMSO. Aliquots were stored in -20 °C. 
 
CHIR stock solution 
(Manufacturer’s protocol) 
To prepare a stock solution of 10 mmol/L dissolve CHIR (Stemolecule™ CHIR99021; 
Stemgent #04-0004) in DMSO. Aliquots were stored in -20 °C. 
 
bFGF stock solution 
(Manufacturer’s protocol) 
To prepare a stock solution of 10 µg/ml dissolve bFGF (Recombinant Human FGF-
basic [154 aa]; Peprotech #AF-100-18B) in 1x PBS with 0.1% HSA (Sigma-Aldrich 
#A9731). Aliquots were stored in -20 °C. 
 
IGF-1 stock solution 
(Manufacturer’s protocol) 
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To prepare a stock solution of 100 µg/ml dissolve IGF (Recombinant Human IGF-1; 
Peprotech #AF-100-11) in 1x PBS with 0.1% HSA (Sigma-Aldrich #A9731). Aliquots 
were stored in -20 °C. 
 
VEGF stock solution 
(Manufacturer’s protocol) 
To prepare a stock solution of 5 µg/ml dissolve VEGF (Animal-Free Recombinant 
Human VEGF [165 aa]; Peprotech #AF-100-20) in 1x PBS with 0.1% HSA (Sigma-
Aldrich #A9731). Aliquots were stored in -20 °C. 
 
TGF-ß1 stock solution 
(Manufacturer’s protocol) 
To prepare a stock solution of 5 µg/ml dissolve TGF-ß1 (Recombinant Human TGF-
ß1 [CHO cell derived]; Peprotech #AF-100-21C) in 1x PBS with 0.1% HSA (Sigma-
Aldrich #A9731). Aliquots were stored in -20 °C. 
 
Polybrene stock solution 
To prepare 1 mg/mL stock 10 mg of hexadimethine bromide (Sigma Aldrich) was 
dissolved in 10 ml of PBS or 0.9% NaCl solution (ready purchased). The solution was 
filtered and stored at 4 °C. It was used for transduction at a final concentration of 8 
µg/ml. 
 
Ascorbic acid stock solution 
To prepare a stock solution of 300 mmol/L dissolve 0.87 g of L-ascorbic acid 2-
phosphate sesquimagnesium salt hydrate (Sigma-Aldrich #A8960) in 10 ml of dH2O 
and sterile filtrate it. Aliquots were stored in -20 °C. 
 
10x RPMI 
RPMI powder (RPMI 1640 medium powder; Gibco #52800-035) was dissolved in 10 
ml of dH2O, sterile filtered and stored at 4 °C. 
 
2x RPMI 
2 ml 10 x RPMI 
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0.8 ml B-27® Supplement (50x;Gibco #17504-044) 
0.2 ml P/S (100x.Gibco #15140-122) 
7 ml H2O 
Sterile filtered solution was stored at 4 °C until further use 
 
Accutase digestion solution 
Mix Accutase (Millipore SCR005) with 0.125 % Trypsin (diluted 1:20 from Trypsin 2.5 
% stock; Gibco 15090-046) and add 20 µg/ml DNase I. 
 
Collagenase digestion solution 
Dissolve 500 mg of collagenase (Collagenase from Clostridium histolyticum for 
general use, Type I; Sigma-Aldrich # C0130) in 250 ml of 1x PBS with Ca2+/Mg2+ and 
20% FBS (Gibco #10270). Aliquots were stored in -20 °C. 
 
HES2-CM serum-free medium 
500 ml RPMI medium 1640.GlutaMAX™ (Gibco #61870-010) 
5.2 ml P/S (100x;Gibco #15140-122) 
10 ml B-27® Supplement (50x;Gibco #17504-044) 
335 μl Ascorbic acid stock solution (300 mmol/L) 
 
HFF medium 
500 ml RPMI medium 1640.GlutaMAX™ (Gibco #61870-010) 
88.6 ml FBS (Gibco #10270) 
6.2 ml Pen/Strep (100x;Gibco #15140-122) 
 
HFF conditioned medium 
50 ml HESC medium 
25 µl bFGF (final concentration 5 ng/ml; Miltenyi Biotech) 
 
HESC medium 
39.5 ml KO DMEM medium (Invitrogen. #10829) 
10 ml KSR (Knockout Serum Replacement; Invitrogen. #10828) 
0.5 ml P/S (100x;Gibco #15140-122) 
 Appendix 1 
82 
 
0.5 ml MEM-NEAA (100x; Gibco #111450-035) 
0.5 ml L-Glutamine (200 mmol/L; Gibco #25030-024) 
50 µl bFGF (final concentration 10 ng/ml; Miltenyi Biotech) 
 
HESC conditioned medium 
25 ml RPMI medium 1640,GlutaMAX™ (Gibco #61870-010) 
25 ml FBS (Gibco  #10270) 
50 µl P/S (100x; Gibco #15140-122) 
 
Cardiac specification medium 
50 ml HES2-CM serum-free medium 
50 µl IWP4 stock solution (final concentration 5 µmol/L) 
 
Selection medium 
49.5 ml RPMI 1640 (without glucose, without–glutamine; Biological 
Industries/WKS Labor diagnostik #01-101-1A) 
0.25 ml Sodium Lactate (final concentration 2.2 mmol/L; Sigma-Aldrich 
71723) 
0.5 ml P/S (100x;Gibco #15140-122) 
0.1 ml 2-mercaptoethanol (50 mmol/L; Invitrogen #31350010)  
  
TSA culture medium 
500 ml DMEM medium (Gibco  #61965-026) 
50 ml FBS (Gibco #10270) 
5.5 ml P/S (100x;Gibco #15140-122) 
 
TSA low serum medium 
500 ml DMEM medium (Gibco #61965-026) 
25 ml FBS (Gibco #10270) 
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EHM medium (incomplete) 
500 ml IMDM GlutaMAX™ (Gibco #31980030) 
5.5 ml P/S (100x;Gibco #15140-122) 
5.5 ml L-Glutamine (200 mmol/L; Gibco #25030-024) 
5.5 ml MEM-NEAA (100x; Gibco#111450-035) 
500 µl Ascorbic acid (stock solution: 300 mmol/L) 
  
EHM medium (complete) 
50 ml EHM medium (incomplete) 
2 ml B-27® minus insulin (50x;Gibco #A18956-01) 
50 µl bFGF stock solution (final concentration 10 ng/ml) 
50 µl IGF-1 stock solution (final concentration 100 ng/ml) 
50 µl VEGF stock solution (final concentration 5 ng/ml) 
 
Freezing medium 
90% FBS (Gibco #10270) 
10% DMSO (Sigma-Aldrich #276855) 
Cell pellets were resuspended in FBS mixture with DMSO and then transferred into 
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Reagents for redox measurement 
 
KCl stock solution 
To prepare 1 mol/L stock solution, 18.64 g of KCl was dissolved and filled up to 250 
ml of dH2O. The solution was stored at RT. 
 
MgCl2 
To prepare a 1 mol/L stock solution, 50.82 g of MgCl2 was dissolved and filled up to 
250 ml of dH2O. The solution was stored at RT. 
 
CaCl2  
To prepare 1 mol/L stock solution, 26.75 g of CaCl2 was dissolved and filled up to 
250 ml of dH2O. The solution was stored at RT. 
 
Imaging buffer 
144 mmol/L   NACl 
5.4 mmol/L    KCl 
1 mmol/L   MgCl2 
10 mmol/L   HEPES 
1 mmol/L   CaCl2 
For the preparation of the imaging buffer, the ingredients listed above (1 mmol/L or 2 
mmol/L of CaCl2 for CMs and HFFs, respectively) were dissolved in dH2O and pH 
gradient was adjusted to 7.3. The buffer was stored at RT. 
 
H2O2solution 
The stock solution 30% H2O2 (Mw = 34.01 g/mol; Sigma-Aldrich #7722-84-1) was 
equivalent to 10 mol/L (d= 1.11 g/ml) and was store at 4 °C. Dilutions of (0.1 - 1,000 
µmol/L) were freshly prepared for each experiment. 
 
Diamide stock solution 
To prepare a stock solution of 1 mol/L, 1 g of diamide (Mw = 172.19 g/mol; Sigma 
Aldrich #10465-78-8) was diluted into 5.8 ml dH2O. The solution was filtered, aliquot 
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and stored at -20 °C.  Dilutions of (1 - 1,000 µmol/L) were freshly prepared for each 
experiment. 
 
DTT stock solution 
To prepare a stock solution of 1 mol/L dissolve 1.54 g of DTT (Sigma Aldrich #3483-
12-3) in 10 ml dH2O. The solution was filtered, aliquot and stored at -20 °C. Dilutions 
of (0.1 – 1 mmol/L) were freshly prepared for each experiment. 
 
Angiotensin II stock solution 
To prepare a stock solution of 5 µmol/L dissolve 1 mg of Angitensin II (Sigma-Aldrich 
#4474-91-3) into 40 µl of dH2O. The solution was further dissolved in 200 ml of dH2O 
and aliquots were stored at -20 °C. Dilutions of (0.1 - 1,000 nmol/L) were freshly 
prepared for each experiment. 
 
Levosimendan stock solution 
To prepare a stock solution of 1 mmol/L dissolve 5 mg of Levosimendan (Sigma-
Aldrich 141505-33-1) in 178 µl of DMSO. The solution was thoroughly dissolved into 
17.8 ml of dH2O and aliquots were stored at -20 °C. Dilutions of (0.1 - 10 µmol/L) 
were freshly prepared for each experiment. 
 
Omecamtiv mecarbil (CK-1827452) stock solution 
To prepare a stock solution of 1 mmol/L dissolve 5 mg of omecamtiv mecarbil (CK-
1827452; AdooQ Bioscience #A11206) in 124.6 µl of DMSO. The solution was 
thoroughly dissolved into 12.46 ml of dH2O and aliquots were stored at -20 °C. 
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Reagents for Immunoblotting 
 
6x Laemmli loading buffer (non-reducing) 
3 ml  Tris-HCl 0.5 mol/L (pH 6.8) 
1.2 g  SDS 
0.75 ml Bromophenol blue (0.5%) 
1.5 ml  Glycerin (100%) 
All the ingredients were dissolved and filled up to 9 ml with H2O. For a reducing gel, 
150 µl 2-ß-Mercaptoethanol was added into the final solution. Aliquots were stored at 
-20 °C. 
 
1.5 mol/L Tris-HCl pH 8.8 
90.85 g of Tris-HCl was dissolved and filled up to 500 ml of dH2O. pH was adjusted 
to pH 8.8. 
 
0.5 mol/L Tris-HCl pH 6.8 
30.28 g of Tris-HCl was dissolved and filled up to 500 ml of dH2O. pH was adjusted 
to 6.8 
 




for 2 gels 
6% 8% 10% 12% 15% 
Protein size (KDa) 150-50 105-40 90-25 60-20 45-10 
H2O 5.3 4.6 4.0 3.3 2.3 
30 % Acrylamide 2.0 2.7 3.3 4.0 5.0 
1.5 M Tris pH 8.8 2.5 2.5 2.5 2.5 2.5 
10 % SDS 0.1 0.1 0.1 0.1 0.1 
10 % APS 0.1 0.1 0.1 0.1 0.1 
TEMED 0.008 0.006 0.004 0.004 0.004 




Volume (ml) 4 gels 
H2O 5.6 
30 % Acrylamid 0.85 
0.5 M Tris pH 6.8 2.5 
10 % SDS 0.1 




10x Electrophoresis / Running buffer (pH 8.3 – 8.7) 
60.6 g  Tris-Base 
288 g  Glycine 
20 g  SDS 
All the ingredients were dissolved and fully mixed in 1 L dH2O and filled up to 2 L of 
dH2O. For every running of gel electrophoresis, 1x running buffer (1:10 dilution) was 
freshly prepared.  
 
10x Transfer buffer 
60.5 g  Tris-Base 
288 g  Glycine 
The ingredients were fully dissolved in 2 L dH2O. 
 
1x Transfer buffer 
200 ml 10 x Transfer buffer 
400 ml Methanol 
The complete solution was filled up to 2 L of dH2O. 
 
10x TBS stock solution 
121.14 g Tris-Base 
175.32 NaCl 
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The ingredients were dissolved in 1.5 L of H2O and stirred until fully dissolved. pH 
was adjusted to 7.5 by using fuming HCl. The final solution was filled up 2 L of H2O. 
 
1x TBST solution 
100 ml 10x TBS 
900 ml H2O 
1 ml  Tween 20 
All the ingredients were mixed until fully dissolved.  
 
Preparation of PVDF membrane 
Activation of PVDF membrane was done by immersing it for 10 sec in 100 % 
Methanol, followed by a washing step for 5 min in dH2O and equilibrating it for 5-10 
min in transfer buffer. 
 
Ponceau staining 
Membranes were incubated for 1-3 min at RT in Ponceau S-solution (Applichem) and 
then rinsed with dH2O to remove the extra red solution. After the staining, protein 
bands appear red colored and this color was rinsed by TBST solution. 
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Reagents for isomeric measurement 
CaCl2 stock solution 
To prepare stock solution of 2.25 mol/L dissolve 165.57 g of CaCl2 x 2H2O in 500 ml 
of dH2O. The stock was stored at 4 °C. 
 
MgCl2 stock solution 
To prepare a stock solution of 1.05 mol/L dissolve 106.83 g of MgCl2 x 6H2O in 500 
ml of dH2O. The stock was stored at 4 °C. 
 
Stock I solution (0.2 mmol/L Calcium) 
175 g  NaCl 
10 g  KCl 
2.22 ml CaCl2 stock solution (2.25 mol/L) 
25 ml  MgCl2 stock solution (1.05 mol/L) 
The ingredients were dissolved and filled up till 1 L with dH2O. The stock was stored 
at 4 °C. 
 
Stock II solution 
50 g of NAHCO3 was dissolved into 1 L of dH2O and stored at 4 °C. 
 
Stock III solution 
5.8 g of NAH2PO4 was dissolved into 1 L of dH2O and stored at 4 °C. 
 
Tyrode’s solution 
200 ml Stock I solution (0.2 mmol/L Calcium) 
190 ml Stock II solution 
50 ml  Stock III solution 
5 g  D-Glucose 
500 mg Ascorbic acid 
The ingredients were dissolved and filled up to 5 L of dH2O. The Tyrode’s solution 
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Reagents for Immunstaining and Flow Cytometry 
 
Permealizing blocking buffer 
26.3 ml Goat serum 
5.26 g  Bovine serum albumin (BSA; Sigma-Aldrich #A3311) 
2.63  Triton X-100 
The ingredients were dissolved and filled up to 500 ml of 1x PBS. The solution was 
stored at 4 °C. 
 
Non-permealizing blocking buffer 
The buffer was prepared by adding 5% of FBS (Gibco #10270) into 1x PBS solution 
























Table 12: Cell lines. 
Cell line Genetic Background Source 
TSA201 
Human Embryonic kidney immortalized 
by an adenovirus serotype 5, SV40 
large T-antigen 
Cells used for lentiviral 
production 
HFFs Human Foreskin Fibroblasts. wild type 
Purchased from American 




Human Foreskin Fibroblasts with 
lentiviral transduction of pGIPZ 
Transgenic modification via 
lentiviral transduction 
roGFP2-HFF 
Human Foreskin Fibroblasts with 
lentiviral transduction of pGIPZ-CMV-
Grx1-roGFP2 
Transgenic modification via 
lentiviral transduction 
HES2-RFP 
HES2 line (Embryonic Stem cell 
International) (Reubinoff et al. 2000) 
including tdRFP knock-in in ROSA26 
locus 
Kindly provided by Gordon 
Keller (Irion et al. 2007) 
HES2-RFP 
CM 
Human cardiomyocytes derived from 
HES2-RFP 
See section 2.1.3.1 
HES2-RFP 
CM (pGIPZ) 
HES2-RFP CM with lentiviral 
transduction of pGIPZ 





HES2-RFP CM with lentiviral 
transduction of pGIPZ-CMV-Grx1-
roGFP2 
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